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1 Introduction 
 
1.1 Diabetes mellitus type 2 
Diabetes mellitus comprises a group of chronic diseases, affecting about 346 
million people worldwide. Over the last decades, the number of patients suffering from 
diabetes mellitus have drastically increased and are expected to tend to 440 million in the 
year 2030 (1). Diabetes mellitus is characterized by deregulation of glucose homeostasis. 
The hormone Insulin, released from pancreatic β-cells in response to food intake, plays a 
central role in the etiology of diabetes. Under non-pathogenic conditions, insulin 
maintains glucose homeostasis by stimulation of glucose uptake from the circulation into 
insulin target tissues (for review see (2)). Among the described forms of the disease type 
2 diabetes mellitus (T2DM) is the most common, comprising about 90% of diabetes cases 
(3). T2DM is characterized by the development of insulin resistance in insulin target 
tissues as well as insulin secretory dysfunction (for review see (3-5)). The development 
of insulin resistance is a rather slow process, accompanied by an initial compensatory 
rising, but finally discontinued, insulin secretion (6). The incapability to respond to 
insulin results in hyperglycemia, i.e. elevated blood glucose levels, a characteristic 
indication of T2DM (for review see (7)). Further common symptoms are loss of weight, 
fatigue and polyuria (for review see (8,9)). Untreated T2DM may lead to serious acute 
complications, like diabetic ketoacidosis and diabetic hyperglycemic hyperosmolar coma, 
both leading to death (10-12). Long-term complications include the development of 
neuro-, angio-, nephro, and retinopathy and increased risk of cardiovascular diseases and 
strokes (10-12). The emergence of T2DM is strongly positively correlated with obesity 
and reduced physical activity, but genetic predispositions are assumed to be an important 
factor as well. (13-15). To date, the exact molecular mechanisms leading to the 
development of insulin resistance remain to be elucidated. Nonetheless, it has been 
suggested that both insulin resistance and β-cell dysfunction are induced by the enhanced 
release of free fatty acids (FFA) and pro-inflammatory mediators from the adipose tissue 
during the course of obesity (16-18). As diabetes emerges from a severe malfunction of 
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insulin signaling, detailed investigation of it´s function and interaction with related 
pathways is of central importance for a deeper understanding of this disease and 
subsequent improvement of treatment strategies. 
 
 
1.2 The Insulin signaling system 
 
1.2.1 Biological functions of the insulin signaling system  
 Signaling through insulin is considered to be the major regulatory mechanism of 
glucose and energy homeostasis. Insulin is a peptide hormone released by the β-cells of 
the pancreatic islets of Langerhans mainly in response to high levels of blood glucose, 
amino acids and lipids after food ingestion (19-23). 
In its target tissues, particularly skeletal muscle, adipose tissue and liver, insulin regulates 
diverse processes involved in glucose uptake and metabolism. Broadly spoken, insulin is 
a signal to occupy externally supplied energy substrates instead of utilizing stored energy 
reserves. Insulin promotes the uptake of glucose in muscle and adipose tissue via 
translocation of the insulin responsive glucose transporter 4 (GLUT4) to the plasma 
membrane and stimulates glucose catabolism via glycolysis (24-26). Furthermore, insulin 
promotes the storage of substrates for energy metabolism by activating glycogen 
synthesis in liver, lipogenesis in adipose tissue and protein synthesis in muscle. On the 
other hand insulin inhibits the opponent processes, lipolysis, glycogenolysis and protein 
degradation (for review see (27)). Aside from its role in peripheral glucose homeostasis, 
insulin has been shown to reduce food intake via the central nervous system by acting on 
the hypothalamus (28-29). In addition to the acute effects of insulin on energy 
homestasis, it acts as a common growth factor by modulating mitosis and differentiation 
(for review see (27, 30)). 
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1.2.2 Insulin, structure and release 
Insulin consists of two peptides, A- and B- chains, cleaved from a single 
precursor, proinsulin (31). Serum Insulin concentration is predominantly controlled 
through the release and not de novo synthesis of insulin (32-33). The most important 
acute signal leading to secretion of insulin from the β-cells is a rise in blood glucose level 
above a specific threshold (34, 35). β-cells absorb glucose via facilitated diffusion 
through glucose transporter GLUT2 (36, 37). Metabolism of absorbed glucose is 
subsequently leading to the release of insulin from secretory vesicles into the blood 
stream (for review see (38)). Beside glucose, increasing plasma levels of amino acids, 
lipids, Glucagon-like-peptide-1 (GLP-1) and Gastric inhibitory polypeptide (GIP), 
gastrointestinal hormones released after food intake (39, 40), and stimulation of the 
parasympathetic nervous system (for review see (41)) trigger the release of insulin. 
  
 
1.2.3 Insulin receptor and post receptor signaling  
The gateway to transmit the signal of circulating insulin into target tissue cells is 
the insulin receptor (IR). IR belongs to a subfamily of receptor tyrosine kinases and is 
expressed almost ubiquitously in mammalian tissues (42-47. The heterotetrameric 
transmembrane receptor is composed of two α/β-dimers connected by disulfide bridges 
(48, 49). The extracellular α-subunits constitute the ligand binding site whereas the β-
subunits span the membrane and comprise the intrinsic tyrosine kinase activity in their 
intracellular portion (50-51). Upon binding of insulin, the α-subunit induces 
conformational changes of the β-subunit, leading to derepression of the tyrosine kinase 
activity. Trans-autophosphorylation at specific tyrosine residues (Tyr) provokes fully 
kinase activity and allows phosphorylation of cytoplasmic substrates binding the receptor 
(52-55). Most prominent among those is the family of insulin receptor substrates (IRS), 
IRS-1 to IRS-5. IRS-1 and IRS-2 seem to play the most crucial role. (56). Further 
substrates are Grb-2 associated binder (Gab), 14-3-3 proteins, SH2-containing protein 
(Shc) and others (57-59). These messengers distribute the signal from the IR into the 
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phospatidylinisitol-3-kinase (PI3K)/Akt and the mitogen-activated protein kinase 
(MAPK) pathway, as the major downstream pathways. 
The PI3K/Akt pathway triggers the majority of acute responses to insulin on 
glucose and lipid metabolism, stimulating glucose uptake and the synthesis of glycogen, 
proteins and triglycerides as well as the expression of genes involved in glucose and lipid 
metabolism (60-62). PI3K is activated through binding to phosphorylated IRS and 
catalyses the transformation of the membrane lipid phosphatinositol-4,5-bisphosphate 
(PIP2) to phosphatinositol-3,4,5-triphosphate (PIP3) (60). The serine kinase AKT binds 
PIP3 and thereby is collocated with the activating kinases phospoinositide-dependent 
protein kinase 1 (PDK1) (63, 64) and mammalian target of rapamycin complex 2 
(mTORC2) (65, 66). Activated by those, AKT functions as a key regulator passing the 
signal to multiple downstream targets promoting glucose uptake, glycogen synthesis, 
protein synthesis and gene expression (for review see (27, 67, 68)) (Fig. 1). 
In contrast to acute metabolic reactions, the MAPK pathway controls the 
mitogenic and differentiation response to insulin (for review see(30)). The signal of  the 
activated IR is transmitted to the MAPK pathway through phosphorylated IRS and Shc 
by recruitment of growth factor receptor bound protein 2 (Grb2). Grb2 recruits Son of 
Sevenless (SOS). Colocalization of SOS and rat sarcoma protein (Ras) at the cell 
membrane leads to activation of Ras through exchange of Guanosine-5'-
diphosphate(GDP) for Guanosine-5'-triphosphate (GTP) (69, 70). Activated Ras elicits a 
cascade of successive activating serine (Ser) phosphorylations of Raf, mitogen-activated 
protein kinase kinase (MAP2K) and finally mitogen-activated protein kinase (MAPK). 
Activated MAPK enters the nucleus and promotes the expression of several genes giving 
a positive signal to growth and differentiation (for review see (27, 30)) (Fig. 1). 
 
 
1 Introduction 
                                                               
 
-5- 
 
 
 
Fig. 1: Insulin receptor signal transduction via PI3K/Akt and MAPK pathway. Binding of insulin to 
the insulin receptor (IR) triggers the activation of it´s tyrosine kinase activity by autophosphorylation. The 
PI3K/Akt pathway is induced by insulin receptor substrate- 1 and 2 (IRS1/2) binding to the activated 
receptor and are phosphorylated by the IR itself.  Phospatidylinisitol-3-kinase (PI3K) is activated by 
binding to phosphorylated IRS-1/2 and catalyses the transition of the membrane lipid phosphatinositol-4,5-
bisphosphate (PIP2) to phosphatinositol-3,4,5-triphosphate (PIP3). Colocation of AKT kinase with it´s 
activating kinases phospoinositide-depent protein kinase 1 (PDK1) and mammalian target of rapamycin 
complex 2 (mTORC2) by their binding to PIP3 is leading to it´s activation. Akt controls a wide range of 
biological functions by acting downstream targets promoting glucose uptake, glycogen synthesis, protein 
synthesis and gene expression. The MAPK pathway is activated by phosphorylation of IRS1/2 or SH2-
containing protein (Shc) by the receptor. Recruitment of growth factor receptor bound protein 2 (Grb2) and 
Son of Sevenless (SOS) activates the GTPase rat sarcoma protein (Ras). Activated Ras induces a cascade of 
successive activating phosphorylations of Raf, mitogen-activated protein kinase kinase (MAP2K) and 
mitogen-activated protein kinase (MAPK). Activated MAPK promotes gene expression by acting on 
several transcription factors. 
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1.3 The insulin like growth factor 1 (IGF1) signaling system 
 
1.3.1 Biological functions of the IGF1 signaling system 
The insulin like growth factor (IGF1) is part of the somatotropic axis, one of the 
major endocrine systems regulating postnatal growth in mammals (71-73). IGF1 is 
mainly released by the liver in response to growth hormone (GH) secretion by the 
anterior pituitary gland (71, 74). Many of the somatic effects of GH are elicited by IGF1 
as intermediary (71, 74). The IGF1 system is structurally closely related to the insulin 
system. The circulating hormone IGF1 and its cognate receptor, the IGF1 receptor 
(IGF1R), display high degrees of homology in sequence and structure with insulin and 
IR. Moreover, both systems trigger MAPK and PI3K/Akt pathways as their major 
intracellular downstream pathways (48, 75-77). 
Despite the close relation between the two systems the well established biological 
effects of insulin and IGF1 signaling differ considerably. Whilst the major effects of 
insulin are thought to be regulation of energy homeostasis, IGF1 is mostly seen as an 
anabolic hormone and as a potent inhibitor of apoptosis (78-81). Deregulation of the 
IGF1 system is mainly correlated with the development of several types of cancer (for 
review see (82)). However, a growing numbers of studies suggest a role of IGF1 
signaling in maintaining glucose homeostasis, a role to the IGF1 system in the 
development of diabetes mellitus (83-91). 
 
 
1.3.2 IGF1, structure and release  
Beside the liver as the major contributor, IGF1 is synthesized and released at a 
lower degree by almost any tissue in an autocrine and paracrine fashion (71, 74, 90). 
IGF1 is a single chain hormone, displaying a high level of homology with insulin, 
showing 48% amino acid identity, identical bonding by disulfide bridges and similar 
tertiary structure (75). In contrast to insulin, IGF1 does not circulate in a free, unbound 
form. About 99% of circulating IGF1 is bound to one of six IGF1 binding proteins 
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(IGFBP1-6) or to one of nine IGFBP related proteins (IGFBP-rP1-9) (91-94). IGFBPs 
play a critical role in IGF1 signaling by prolonging half-life of IGF1, regulating intra- 
and extravascular transport and affecting their affinity for receptor binding (92, 95, 96).   
 
 
1.3.3 The IGF1 receptor and post receptor signaling  
The IGF1R is expressed almost ubiquitously (97). As insulin and IGF1, IR and 
IGF1R display a high degree of homology, the same tertiary structure and do share the 
same mechanism of receptors activation and signal transduction. (48, 77, 98). Like IR, 
the IGF1R is a tetrameric receptor tyrosine kinase, composed of two extracellular α and 
two membrane spanning β subunits, bearing an intracellular tyrosine kinase domain (99-
101). IGF1R and IR share approximately 70% amino acid homology, with 84 % as the 
highest degree in the tyrosine kinase domain (48, 102). Notably, IR and IGF1R display 
short highly heterogeneous sequences in their tyrosine kinase domains and further 
sequences of low homology in their carboxyl terminal domains (48). These differences 
may be in part responsible for distinctions in the downstream signaling and the biological 
effects of the both receptors.  
The process of IGF1R activation is very similar to the previously described 
activation of IR. Hormone binding to the IGF1R activates its intrinsic tyrosine kinase 
activity gaining full activity after initial trans-phosphorylations (for review see (103)). 
Activated IGF1R triggers diverse pathways by recruitment and phosphorylation of IRSs, 
Shc, Grb2 and 14-3-3 proteins (79-81, 104, 105). Among those, PI3K/Akt and MAPK 
pathway mediate most of IGF1´s effects and are the best investigated. The PI3K/Akt 
pathway is activated as previously described for IR signaling (Fig. 1). Anti-apoptotic and 
protein synthesis stimulating effects of IGF1 are mediated mainly via activation of Akt. 
Anti-apoptotic effects are induced by inhibitory phosphorylation of pro-apoptotic factors, 
as well as increased expression of anti-apoptotic proteins (103, 106-108). Furthermore 
Akt exerts a generally stimulating effect on protein synthesis (109). Activation of the 
MAPK pathway by IGF1R is associated with the effects of IGF1 on cellular proliferation 
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and differentiation by promoting expression of genes promoting mitosis (110, 111). 
Mechanisms of activation are the same for triggering MAPK via IR and IGF1R (Fig. 1).  
The fact that insulin and IGF1 signaling cause such unequal biological effects by 
triggering the same major intracellular pathways appears conflicting. Selective outcome 
of insulin and IGF1 signals is assumed to depend on differences in the recruitment of 
intracellular docking proteins resulting from different substrate specificities, binding 
velocities, reaction times and activities (112, 114-116). In part, different ligand binding 
behavior might be explained by the mentioned sequence variations in the tyrosine kinase 
domains and the carboxyl terminal domains of IR and IGF1R (48).  
 
 
1.3.4 Crosstalk events between insulin and IGF1 systems 
Due to homology in amino acid sequence and in structure of the hormones and 
receptors interferences among insulin and IGF1 system occur. Insulin binds and activates 
IGF1R as well as IGF1 is capable of binding and activating IR (117). The binding 
affinities are indeed much lower than binding to their cognate receptors, making non 
physiological concentrations of hormones required to achieve receptor activation (91, 
118, 119). Insulin binds to IGF1R with a 100-fold lower affinity than to IR (118). The 
binding affinity of IGF1 to IR is even 1.000-fold lower than the affinity of IGF1 to its 
cognate receptor (for review see (91, 119)). In this context, it is important that serum 
concentrations of IGF1 in human are 100-fold higher than concentrations of insulin (for 
review see (120)). More relevant than notional receptor binding seems to be the 
formation of functional hybrid receptors through the assembly of IR and IGF1R α/β- 
hemireceptors (121, 122). Hybrid receptors display low affinity to insulin, but high 
affinity to IGF1, at levels comparable to IGF1R (123-125). Until now, the biological 
response triggered by these hybrid receptors and their biological function remains unclear 
(for review see (126)). 
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Fig. 2: Crosstalk between insulin and IGF1R systems. Close structural homology between receptors and 
hormones allows crosstalk between both systems through binding of insulin and IGF1 to non cognate 
receptors and the formation of hybrid receptors between IR and IGF1R hemireceptors. Insulin and IGF1 
bind to each of these receptors, IRs, IGF1Rs and hybrid receptors, however with variable affinities. Insulin 
affinity to IGF1R and IR/IGF1R hybrid receptors is about 1,000-fold lower (dotted arrow) than to its 
cognate IR (solid arrow). IGF1 binds IGF1R and IR/IGF1R hybrid receptors with almost same affinity 
(solid arrow), whilst IR is bound with 100-fold lower affinity (dashed arrow). 
 
 
1.3.5 The IGF1 system in the context of glucose metabolism 
The close structural relation between insulin and IGF1 signaling systems suggest 
the possibility of redundant biological functions among IR and IGF1 system. As a matter 
of fact, there are increasing numbers of evidences from clinical trails as well as in vitro 
and in vivo studies suggesting a role of the IGF1 system in glucose homeostasis and the 
development of diabetes. 
Reduced levels of circulating IGF1 are observed in patients suffering from T2DM 
(127). Furthermore, administration of IGF1 has shown to reduce serum glucose levels in 
healthy humans and individuals suffering from T2DM (128-131). However, the 
magnitude of these insulin-like effects of IGF1R is only 4-7 % of that of insulin (85, 87). 
Furthermore, improved insulin sensitivity was demonstrated after IGF1 administration in 
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several of these studies (88, 130, 131). As observed for IGF1 itself, reduced levels of 
IGFBPs are associated with hyperglycaemia (85). In particular, IGFBP1 may be relevant 
for the effects of IGF1 on glucose homeostasis, since treatment with IGFBP1 has shown 
to reduce serum glucose levels in humans (132, 133). Furthermore, mice overexpressing 
IGFBP3 display increased fasting serum glucose levels and impaired glucose tolerance 
(134, 135). 
The role of IGF1R in this context has been demonstrated in mice overexpressing a 
dominant-negative IGF1R mutant in skeletal muscle, leading to functional inactivation of 
IGF1R and IGF1R/IR hybrid receptors and the development of a diabetes-like phenotype 
(87). In contrast, muscle specific inactivation of IR through it´s deletion or 
overexpression of a dominant-negative mutant in mice interestingly just cause a mild 
phenotype and allowed to maintain glucose homeostasis over months (42, 136). Further 
considerations about a role of IGF1R are given by in vitro studies in IR-deficient muscle 
cells and fibroblasts showing increased glucose uptake and glycogen synthesis after 
treatment with IGF1 or high concentrations of insulin (137, 138).  
The effects of IGF1 on glucose clearance are predominately attributed to an IGF1 
induced peripheral glucose uptake in skeletal muscle tissue (87, 89, 137-142). Glucose 
uptake in adipocytes after IGF1 stimulation has been described as well as decreased 
gluconeogenesis in hepatocytes (128, 141). However, both observations 
are controversially discussed. 
Taken together, these studies indicate a potential role of the IGF1 system in the 
context of glucose homeostasis and the etiopathogenesis of diabetes, possibly by adopting 
functions of the IR or by influencing insulin signaling.  
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1.4 Technical background 
1.4.1 Motivation for technical innovation 
In this study the functional redundancy between IGF1R and IR in the context of 
glucose homeostasis has been examined. For this reason novel technical approaches have 
been developed, aiming to generate transgenic mice lacking the function of both 
receptors. The basic concepts for this development are two techniques, the recombinase-
mediated cassette exchange (RMCE) and the use of RNA interference (RNAi). The 
combined application of these techniques is already successfully used to generate 
genetically engineered mice displaying a single gene inactivation (143, 144).  
 
 
1.4.2 RNA interference (RNAi) 
RNA interference (RNAi) is a eukaryotic mechanism of specific 
posttranscriptional gene regulation. Triggers of RNAi are 21 to 28 base pair (bp) long 
double stranded RNAs (dsRNAs) inducing degradation or translational inhibition of 
mRNAs bearing complementary sequences (145, 146). In vertebrates, natural occurring 
RNAi is induced by a non-coding RNA species designated as micro RNAs (miRNAs), 
cleaved out of complex hairpin structures and playing a crucial role in embryogenesis and 
tissue morphogenesis (147-153). This process employs a complex machinery of RNAses 
and multiproteincomplexes (153-157).  
Several techniques have been developed to establish RNAi as an efficient tool for 
the down regulation of a specific gene of interest, designated as knock down (KD), 
suitable application for achievement of in vivo gene silencing in animal models (158). 
The most practical option to specifically induce a target gene KD in mice is the in vivo 
expression of artificial hairpin structures entering the endogenous RNAi pathway (159-
163). Stable integration of expression vectors allows for a constitutive KD by constant 
production of hairpin RNAs (143, 160, 164). The most widely used method is the 
expression of so-called short hairpin RNAs (shRNAs). Those are composed of inverted 
repeats of a 19 to 29 nucleotide sequence, complementary to the target gene, connected 
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by a 6 to 9 nucleotide long spacer sequence. The shRNA transcript forms a hairpin by 
base pairing, constituting a substrate of the endogenous RNAi pathway and being 
processed to a RNA duplex triggering RNAi. Transcribed shRNA is exported actively 
from the nucleus into cytoplasm, where RNAse Dicer produces a duplex intermediate 
with characteristic 2nt 3´overhangs by removal of the loop sequence (154, 165, 166). 
This dsRNA is incorporated into the RNA-induced silencing complex (RISC), the 
effector of RNAi. Only one strain of the duplex remains in the Risc as a guide strand and 
mediates the specific binding of the complex to complementary target sites of mRNAs. 
Perfectly matching guide strands mediate endonuclear cleavage of bound mRNA by 
RISC (149, 150). RISC assembly shows a distinct strand bias favoring the incorporation 
of just one strand of the duplex, probable due to thermodynamic properties of the dsRNA 
intermediate (155, 156). Polymerase III (Pol III) depending promoters such as H1 and U6 
are used for shRNA expression, providing strong and ubiquitous expression of short well 
defined transcripts without poly-A-tails (159, 160, 169, 170). To allow temporary control 
of shRNA expression inducible Pol III promoters have been developed by combining U6 
and H1 with the tetracycline operator/repressor system (144, 171). The possibility to 
induce the KD upon administration of the inductor allows circumventing embryonic 
lethality by target genes loss of function, observed for about 30 % of murine genes. 
Predictable and reproducible KD efficiencies can be archived by targeted integrations of 
expression vectors in characterized and suitable loci. Rosa26 (R26) and hypoxanthine-
guanine phosphoribosyltransferase (Hprt) loci have been used for this issue (143, 172, 
173).  
 
 
 
1 Introduction 
                                                               
 
-13- 
 
 
Fig. 3: RNAi induced by shRNA. The shRNA is expressed from a vector based or stably integrated 
template and enter the endogenous miRNA processing pathway. After export from nucleus into cytoplasm 
the loop structure is removed by Dicer thereby, producing the double strained siRNA. RISC incorporates 
and unwinds the double strain.  One strain of the siRNA remains in the activated from of RISC (RISC*), 
guiding the complex to complementary binding sites of the target mRNA. Expression of the target gene is 
repressed by cleavage and subsequent degradation of bound mRNA. 
 
Generation of loss of function mutants by using RNAi technology is directly 
competing with knockout (KO) mice achieving loss of function by partial or complete 
deletion of the gene of interest (GOI) by homologous recombination (158). Compared to 
KOs, there are several advantages of the RNAi technology, but disadvantages as well. 
First, a KD results in a reduction to 5 to 40 % of the original target mRNA level and not 
in a complete loss of function, as it is true for KOs (143, 174). In particular cases, a 
milder phenotype resulting from the remaining gene product offers a better-suited model 
for physiological conditions than a complete loss of function. On the other hand residual 
gene activities might complicate phenotype analysis in reverse genetic studies. A major 
advantage of RNAi is the short time needed for the generation of mouse KD mice. RNAi 
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alleles are acting in trans and thus do not have to be breed into homozygosity (143, 175). 
Furthermore, highly efficient recombinase based integration systems can be used for 
integration of shRNA expression vectors at predefined loci, since the mechanisms of 
RNAi are independent from the target gene´s genomic site and structure (143, 144). At 
last about 12 month are required to generate homozygote KO mice, whereas KD mice 
can be generated in just 7 month (143, 176). Problematic about artificial RNAi are 
potential off target effects, the unwanted KD of partially complementary mRNAs or 
unspecific effects due to immune stimulation (177-180). Options for the recognition of 
unspecific phenotypes originating from off target effects are given by control 
experiments using another shRNA sequence designed against the same target gene or co-
expression of rescue mutants, designed target gene mutants bearing no target sequence of 
the used shRNA (181). 
 
 
1.4.3 Recombinase mediated Cassette Exchange (RMCE) 
The recombinase-mediated cassette exchange (RMCE) is a technique to perform 
the stable integration of transgenic elements by the exchange of a vector based donor 
cassette and a genomic acceptor cassette at previously prepared allele.  
RMCE systems utilize the reaction catalyzed by sequence specific recombinases, FLP 
and Cre, in the first instance. These enzymes recombine DNA within their short 
recognition sites, the FLP recombinase recognition target (FRT) and the locus of 
crossover in P1 (loxP) of the Cre recombinase, at a very high frequency (182, 183). The 
basic principle of RMCE systems is the use of two couples of heterospecific recognition 
sites, e.g. a combination of loxP and FRT sites, or of wild type recognition site and an 
incompatible mutated sited (184-187). Two incompatible recognition sites in the same 
configuration flank donor and acceptor cassettes. In the presence of the corresponding 
recombinase just the compatible sites of vector and RMCE allele are recombined. 
Through this double reciprocal recombination, transposition of the cassettes between 
genome and vector is carried out (Fig. 4). The incompatible character of the available 
recognition sites prevents intramolecular reactions. Thus, even in the presence of the 
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recombinase, the exchanged cassette remains stably integrated. RMCE insertions occur at 
a very high frequency up to 95% in cultured murine embryonic stem (ES) cells (143, 
188). Nevertheless, to achieve a genomic locus prepared for RMCE integration, targeting 
of this locus by classical integration techniques is required (143, 188, 189, 193). The 
RMCE technique is beneficial in the case of the need for repeated integration of different 
elements at the same loci, e.g. the expression of transgenic mRNAs, research on 
regulatory elements, creation of multiple mutant alleles or the expression of short RNAs 
for RNAi induction (143, 189, 190).  
 
 
 
Fig.  4: Functionality of Recombinase mediated Cassette Exchange (RMCE).  A RMCE is mediated 
through the enzyme catalyzed recombination of two heterospecific pairs of recognition sites. By this 
reaction the sequences bordered by this recognition sites, a genomic acceptor cassette and a vector based 
donor cassette, are transposed. Due to the incompatibility of the genomic recognition sites the exchanged 
cassette remains stable integrated, even in presence of recombinase. 
 
The donor cassette integrates exclusive of prokaryotic backbone elements of the 
exchange vector, which are known for potential induction of epigenetic changes at the 
site of integration. The stable single copy integration in a predefined locus allows 
predictable and reproducible use of the given expression properties, the major advantage 
of the RMCE technique (144). Recently the potential to perform specific RMCE 
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reactions in two distinct genomic loci in parallel has been shown (191). Specificity for 
the individual loci has been archived by the use of four couples of heterospecific FRT 
variations. 
Within this study a FLP based RMCE system situated in the rosa 26 (R26) locus 
served as a technical basis (143) (Fig. 5). The genomic part of this system is integrated 
into the first intron of the R26 gene, displaying ubiquitous transcriptional activity through 
all stages of mouse development (192).  A phosphoglyceratkinase (PGK) promoter driven 
hygromycin resistance gene inside the acceptor cassette affords positive selection of 
R26(RMCE) bearing cells. Cassette exchange in R26 depends on the application of two 
hetereospecific pairs of wild type FRT sites and mutated recognition sites, designated as 
F3 sites (186). While a 2 bp variation within the recognition sequence inhibits the 
reaction between FRT and F3 sites completely, two F3 sites display the same self-
recognition capacity as the wild type does (184). RMCE reaction is carried out through 
double reciprocal recombination of FRT and F3 pairs bordering acceptor and donor 
cassette in the same configuration, mediated by a co-expressed FLP recombinase. A 
marker system allows antibiotic selection by reconstitution of a non-functional neomycin 
resistance gene (5´dNeo), leaking start codon (ATG) and promoter, upon correct 
exchange. A splice acceptor site (SA) and an ATG facilitate expression of the truncated 
neomycin resistance gene (5´dNeo) on the exchange vector by employing the endogenous 
rosa26 promoter after cassette exchange. Functionality of 5´dNeo is exclusively restored 
by correct recombination of the F3 site, allowing geneticin (G418) selection after proper 
cassette exchange. In case of random integration events, transcription of 5´d Neo is 
prevented by a pA upstream of 5´d Neo on the exchange vector. The Hyg resistance gene 
gets lost in couse of RMCE reaction. 
Stable single copy integration of shRNA or cDNA expression units in R26 takes 
advantage of the well characterized properties of this locus. Integration in R26 RMCE is 
highly efficient, with a frequency up to 95 % in murine ES cells, allowing rapid generate 
of transgenic mice with predictable and reproducible expression properties of inserted 
elements (143). 
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Fig. 5: Functionality of R26 RMCE system. A) The exchange vector contains in 5´-3´direction: 
polyadenylation signal (pA), F3 site, neomycin resistance gene leaking ATG and promoter (5´d Neo), 
insert, FRT site.  B) The genomic part of R26(RMCE) contains following elements in 5´-3´direction: splice 
acceptor (SA), start codon (ATG), F3 site, phosphoglycerate kinase promoter (PGK), hygromycin 
resistance gene (Hyg), FRT site. Hyg allows antibiotic selection of R26(RMCE) cells. Stable expression of 
FLP avoids incomplete recombination events. C) SA and an ATG facilitate expression of 5´dNeo by 
employing the endogenous rosa26 promoter after cassette exchange, allowing G418 selection after correct 
cassette exchange. Hygromycin resistance gets lost upon RMCE. 
 
 
1.5 Objectives 
The aim of this study was to examine the functional redundancy between IGF1R 
and IR in the context of energy homeostasis. For this reason novel technical approaches 
have been developed, allowing the shRNA mediated KD of two independent target genes 
in transgenic mice. Two different strategies were pursued to reach this aim. 
The first strategy was based on the generation of a murine ES cell line harbouring two 
irrespective RMCE acceptor cassettes at independent genomic loci. Such a cell line 
should enable the integration of two different shRNA expression cassettes in the two 
RMCE loci. As a second strategy two shRNA expression units were combined in a single 
RMCE donor cassette for integration into the R26 RMCE locus. This method was applied 
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for generation of a mouse model providing the concurrent KD of the insulin and the IGF1 
receptor. These mice were physiologically characterized in terms of energy homeostasis. 
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2 Material and Methods 
 
2.1 Chemicals and Enzymes 
Chemicals and enzymes used in this work and the respective sources of supplies 
are indicated below, chemicals in table 1 and enzymes in table 2. 
 
Chemical Supplier 
α-[32P]-dCTP PerkinElmer Life Science, Cologne, Germany 
β-mercaptoethanol Fisher Scientific, Schwerte, Germany  
10x PCR buffer Invitrogen, Karlsruhe, Germany 
20x saline-sodium citrate (SSC) Invitrogen, Karsruhe, Germany  
4-2-hydroxyethyl-1-piperazineethanesulfonic  
acid  (HEPES) 
Sigma Aldrich, Steinheim, Germany 
Adenosintriphosphat (ATP), 10 mM Invitrogen, Karlsruhe, Germany 
Agarose ultra pure Sigma Aldrich, Steinheim, Germany  
Albumine from bovine serum Sigma Aldrich, Steinheim, Germany  
Ampicilin VWR International, Langenfeld, Germany  
Bovine Serum Albumin (BSA) Santa Cruz Biotechnology, Santa Cruz, USA 
Bromophenol blue Merck, Darmstadt, Germany  
Chloroform Merck, Darmstadt, Germany 
Complete protease inhibitor cocktail tablets Roche Diagnostic, Mannheim, Germany 
Desoxyribonukleotide triphosphate set  
(dNTP)    
5 Prime, Hamburg, Germany  
Dextran sulfat sodium salt Sigma Aldrich, Steinheim, Germany 
Dimethyl Sulfoxide (DMSO)  Sigma Aldrich, Steinheim, Germany 
Dithiothreitol (DDT) Sigma Aldrich, Steinheim, Germany 
Dulbecco's Modification of Eagle's Medium 
(DMEM) 
Fisher Scientific, Schwerte, Germany 
Doxycycline hyclate Sigma Aldrich, Steinheim, Germany  
2 Material and Methods 
                                                               
 
-20- 
 
Ethanol absolute Merck, Darmstadt, Germany  
Ethidium bromide tablets VWR International, Langenfeld, Germany  
Ethylenediaminetetraacetic (EDTA) Sigma Aldrich, Steinheim, Germany 
Fetal calf serum (FCS)  PAN-Biotech, Aidenbach, Germany 
Forward reaction buffer (x5) Invitrogen, Karlsruhe, Germany 
Fugene6 Transfection Reagent  Roche Diagnostics, Mannheim, Germany 
G153 Developer Agfa Healthcare, Mortsel, Belgium  
G354 Fix  Agfa Healthcare, Mortsel, Belgium  
Geneticin (G418) Sigma Aldrich, Steinheim, Germany 
Glucose 20% Bela-pharm, Vechta, Germany  
Glycerol Merck, Darmstadt, Germany  
Guanidine hydrochloride AppliChem, Darmstadt, Germany  
Hydrochloric acid (HCl) Sigma Aldrich, Steinheim, Germany 
Hygromycin B in PBS Invitrogen, Karlsruhe, Germany 
Insulin human Novo Nordisk, Basvaerd, Denmark  
Isopropanol TH. Geyer & Co, Renningen, Germany  
Kaliumchloride (KCl) Sigma Aldrich, Steinheim, Germany 
Lysogeny Broth (LB)   Sigma Aldrich, Steinheim, Germany  
Magnesium chloride (MgCl2) Invitrogen, Karlsruhe, Germany  
Magnesium sulfate (MgSO4) Invitrogen, Karlsruhe, Germany 
Modified Eagle Media (MEM), non essential 
aminoacids  
Invitrogen, Karlsruhe, Germany 
 
N-Laurylsacrosinate Sigma Aldrich, Steinheim, Germany 
optiMEM I with Glutamax-I  Invitrogen, Karlsruhe, Germany 
PCR reaction buffer HIFI (x10) Invitrogen, Karlsruhe, Germany 
PeqGOLD TriFast Peqlab, Erlangen, Germany 
Phenol-Chloroform-Isoamyl alcohol Applied Biosystems, Darmstadt, Germany   
Phosphatase inhibitor cocktail tablets,  
PhosSTOP  
Roche Diagnostic, Mannheim, Germany 
Phosphate buffered saline (PBS) Invitrogen, Karlsruhe, Germany  
Protein A Agarose Millipore, Eschborn, Germany 
Puromycin Dihydrochloride  Sigma Aldrich, Steinheim, Germany 
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QIAzol lysis reagent Qiagen, Hilden, Germany  
Reporter gene assay lysis buffer Roche Diagnostic, Mannheim, Germany  
Restriction enzymes and buffers P1 New England Biolabs, Frankfurt, Germany 
Restriction enzymes and buffers P2 New England Biolabs, Frankfurt, Germany 
Restriction enzymes and buffers P3 New England Biolabs, Frankfurt, Germany 
Restriction enzymes and buffers P4 New England Biolabs, Frankfurt, Germany 
RNAlater  Applied Biosystems, Darmstadt, Germany   
Salmon sperm DNA solution ultra pure, 
sonificated  
Fisher Scientific, Schwerte, Germany  
Sodium chloride 0,9% (NaCl) B. Braun, Melsungen, Germany  
Sodium dodecyl sulfate (SDS) Sigma Aldrich, Steinheim, Germany  
Sodium hydroxide (NaOH) VWR International, Langenfeld, Germany  
Sodium pyrophosphate (Na2HPO4) Sigma Aldrich, Steinheim, Germany 
Sodium pyrovate (C3H3NaO3) Sigma Aldrich, Steinheim, Germany 
Sucrose Sigma Aldrich, Steinheim, Germany 
Super Signal West Pico chemiluminescent 
substrate  
Fisher Scientific, Schwerte, Germany  
 
Tris/EDTA (TE) buffer, pH=7.0 Invitrogen, Karlsruhe, Germany 
Tris acetate EDTA (TAE) Fisher Scientific, Schwerte, Germany  
Tris-glycine SDS running buffer Invitrogen, Karlsruhe, Germany  
Triton X-100 Sigma Aldrich, Steinheim, Germany 
Trizma hydrochloride Sigma Aldrich, Steinheim, Germany 
Tween 20 Sigma Aldrich, Steinheim, Germany 
Trypsin-EDTA (0.25%) Gibco, Karlsruhe, Germany 
 
Table 1: Chemicals used in this work.
 
 
 
 
Enzymes Supplier 
AflIII (5,000 U/ml)  New England Biolabs, Frankfurt, Germany 
AscI (10,000 U/ml)  New England Biolabs, Frankfurt, Germany 
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BamHI (10,000 U/ml)  New England Biolabs, Frankfurt, Germany 
BbsI (5,000 U/ml)  New England Biolabs, Frankfurt, Germany 
BclI (15,000 U/ml)  New England Biolabs, Frankfurt, Germany 
BsaBI (10,000 U/ml)  New England Biolabs, Frankfurt, Germany 
BstBI (20,000 U/ml)  New England Biolabs, Frankfurt, Germany 
ClaI (5,000 U/ml)  New England Biolabs, Frankfurt, Germany 
DpnI (20,000 U/ml)  New England Biolabs, Frankfurt, Germany 
EcoRI (10,000 U/ml)  New England Biolabs, Frankfurt, Germany 
FseI (2,000 U/ml)  New England Biolabs, Frankfurt, Germany 
High fidelity (HIFI) platinum taq polymerase 
(5 U/µl) 
Invitrogen, Karlsruhe, Germany 
HindIII (20,000 U/ml) New England Biolabs, Frankfurt, Germany 
HpaI (5,000 U/ml)  New England Biolabs, Frankfurt, Germany 
KpnI (20,000 U/ml)  New England Biolabs, Frankfurt, Germany 
MfeI (10,000 U/ml)  New England Biolabs, Frankfurt, Germany 
MluI (10,000 U/ml)  New England Biolabs, Frankfurt, Germany 
NarI (5,000 U/ml)  New England Biolabs, Frankfurt, Germany 
NcoI (10,000 U/ml)  New England Biolabs, Frankfurt, Germany 
NdeI (20,000 U/ml)  New England Biolabs, Frankfurt, Germany 
NheI (10,000 U/ml)  New England Biolabs, Frankfurt, Germany 
PacI (10,000 U/ml)  New England Biolabs, Frankfurt, Germany 
PmeI (10,000 U/ml)  New England Biolabs, Frankfurt, Germany 
Proteinase K (600 mAU/ml) 5 Prime , Hamburg, Germany 
PstI (20,000 U/ml)  New England Biolabs, Frankfurt, Germany 
PspXI (10,000 U/ml)  New England Biolabs, Frankfurt, Germany 
SbfI (10,000 U/ml)  New England Biolabs, Frankfurt, Germany 
SfiI (20,000 U/ml)  New England Biolabs, Frankfurt, Germany 
SpeI (10,000 U/ml)  New England Biolabs, Frankfurt, Germany 
SwaI (10,000 U/ml)  New England Biolabs, Frankfurt, Germany 
Taq DNA Polymerase Invitrogen, Karlsruhe, Germany 
T4 DNA Polymerase Invitrogen, Karlsruhe, Germany 
T4 Kinase (10 U/µl) Invitrogen, Karlsruhe, Germany 
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T4 Ligase H.C. (12 U/µl) Invitrogen, Karlsruhe, Germany 
XbaI (20,000 U/ml)  New England Biolabs, Frankfurt, Germany 
XhoI (20,000 U/ml)  New England Biolabs, Frankfurt, Germany 
 
Table 2: Enzymes used in this work. 
 
 
2.2 Molecular Biological methods 
 
2.2.1 General cloning cloning procedure 
In general, digested plasmid DNA and annealed oligonucleotides were used for 
cloning DNA constructs. Vector DNA was digested by treatment of 2 µg DNA with 10 U 
of each applied restriction enzyme for 1.5 to 2 h. BSA and restriction enzymes and 
buffers were used according to manufacturer´s instructions.  Digested DNA fragments were 
separated by size using electrophoretic separation in agarose gel (0.8 -1.5 % (w/v), agarose; 1 
x TAE; 0.5 mg/ml ethidium bromide; 1 x TAE electrophoresis buffer) and isolated from gel 
using QIAquick Gel Extraction-Kit (Qiagen, Hilden, Germany), according to manufacturer’s 
instructions. 100 µg vector DNA were used per ligation reaction in a molar vector to 
insert ratio of 3:1, for sticky end ligations, and 5:1 for blunt end ligations. For ligation 
with oligonucleotides 100 µg vector DNA was ligated with 4µl of diluted and annealed 
oligonucleotides, as described below under 2.2.2. DNA was incubated in a total reaction 
volume of 20 µl containing 4µl 5x Ligase Reaction Buffer (Invitrogen, Karlsruhe, 
Germany), 1 U T4 Ligase H.C. (Invitrogen, Karlsruhe, Germany) for 4 h at 16 °C. 
Ligation mixtures were transformed into MaxEfficiency DH5α chemical competent cells 
(Invitrogen, Karlsruhe, Germany), according to manufacturer´s introductions, spread on 
LB plates containing 100 µg/ml ampicillin and incubate overnight at 37 °C. Single 
colonies were analysed for correct ligation product by using CloneChecker™ System 
(Invitrogen, Karlsruhe, Germany) following users manual and subsequent analytic 
restriction digest, adjusted to the accordant cloning product.  
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2.2.2 Annealing of synthetic oligonucleotides for cloning 
Oligonucleotides were used for several cloning steps. For each step two single 
strained oligonucleotides, sense (s) and antisense (as), were designed to be hybridizated 
into double strained DNA bearing overhangs compatible to the overhangs of vector 
fragment they are to be ligated to. Both oligonucleotides are phosphorylated by 
incubating 1 µg of each oligonucleotide with 5 µl 5x forward reaction buffer (Invitrogen, 
Karlsruhe, Germany), 2.5 µl 10 mM ATP (Invitrogen, Karlsruhe, Germany), 1 U T4 
Kinase (Invitrogen, Karlsruhe, Germany) in a total volume of 25 µl at 37 °C for 30 min. 
Kinase was inactivated by subsequent incubation at 65 °C for 10 min. For annealing 14 µl 
of each kinasing mixture were pooled with 4 µl 5M NaCl, incubated at 65 °C for 15 min 
and subsequently cooled down slowly to room temperature. After adding 68 µl TE buffer 
this mixture is diluted 1:10 with ddH2O. 4µl of diluted annealed oligonucleotides are used 
for ligation. All oligonucleotides used in this work were custom synthesized by metabion, 
Martinsried, Germany.  
 
 
2.2.3 Blunting of sticky ended DNA 
Blunting of sticky ends, created by restriction digest, was performed, if further 
procedure includes ligation with blunt ended fragments or abolishing of the restriction 
site by religation of blunted fragment. For blunting 4 µg vector DNA was digested in a 
Volume of 76 µl. After restriction digest 2 µl 10 mM dNTP mix, 20 µl 5 x T4 DNA 
Polymerase Buffer and 2 µl T4 DNA Polymerase (5 U/µl) were added and incubated at 
11°C for 15 min. Fragment were separated in agarose gel electrophoresis and isolated 
from gel as described above under 2.2.1. 
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2.2.4 Cloning of single shRNA expression vectors (pR-shIGF1R1 – pR-shIGF1R6) 
shRNA expression vectors were cloned using oligonucleotides constituted on 
basis of siRNAs designed by the algorithm BLOCK-iT™ RNAi Designer (Invitrogen, 
Karlsruhe, Germany). Used Sequences are displayed in table 3. The sense sequence, 
compatible to target mRNA, with an length of 19 to 21 nt siRNAs was embedded into an 
structure to allow transcripts formation of hairpin structure, termination of Pol III 
transcription and cloning of the oligonucleotide into pINV-7 (TaconicArtemis, Cologne, 
Germany), a standard vector for inducible RNAi and RMCE integration in R26. The 
siRNAs sense strand was connected to its fully complementary antisense strand by a loop 
sequence (TTCAAGAGA) and followed by five thymidines, a Pol III transcription 
termination site. Sense and antisense oligonucleotides (table 3) were designed to form 
overhangs compatible to BbsI/MluI digested pINV-7 (TaconicArtemis, Cologne, 
Germany) after annealing. Strands order relative to H1tetO promoter is sense strand 
followed by antisense strand. All oligonucleotides were purchased from metabion, 
Martinsried, Germany. Oligonucleotides were annealed, ligated to BbsI/MluI digested 
pINV-7 to yield pR-shIGF1R1 to pR-shIGF1R6. All Oligonucleotides were purchased 
from metabion, Martinsried, Germany.  
 
shRNA Sequence of sense strand (5´-3´) Oligonucleotides, name and sequence (5´-3´) 
oshIGF1R1_s: 
CCCGCAATCTGCTTATTAACATCCTTCAAGAG
AGGATGTTAATAAGCAGATTGCTTTTTA 
shIGF1R1 
 
GCAATCTGCTTATTAACATCCT 
oshIGF1R1_as: 
CGCGTAAAAAGCAATCTGCTTATTAACATCC
TCTCTTGAAGGATGTTAATAAGCAGATTGC 
oshIGF1R2_s: 
TCCCGGAAGAACCGAATCATCATAATTCAAG
AGATTATGATGATTCGGTTCTTCCTTTTTA 
shIGF1R2 GGAAGAACCGAATCATCATAA 
 
oshIGF1R2_as: 
CGCGTAAAAAGGAAGAACCGAATCATCATA
ATCTCTTGAATTATGATGATTCGGTTCTTCC 
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oshIGF1R3_s: 
TCCCGCACAACTACTGCTCCAAAGATTCAAG
AGATCTTTGGAGCAGTAGTTGTGCTTTTTA 
shIGF1R3 GCACAACTACTGCTCCAAAGA 
 
oshIGF1R3_as: 
CGCGTAAAAAGCACAACTACTGCTCCAAAGA
TCTCTTGAATCTTTGGAGCAGTAGTTGTGC 
oshIGF1R4_s: 
TCCCGGACAGATCCTGTGTTCTTCTTTCAAGA
GAAGAAGAACACAGGATCTGTCCTTTTTGGT
AC 
shIGF1R4 GGACAGATCCTGTGTTCTTCT 
 
oshIGF1R4_as: 
CGCGGTACCAAAAAGGACAGATCCTGTGTTC
TTCTTCTCTTGAAAGAAGAACACAGGATCTG
TCC 
oshIGF1R5_s: 
TCCCCCATCAGGATTGAGAAGATTCAAGAGA
TCTTCTCAATCCTGATGGTTTTTA 
shIGF1R5 CATCAGGATTGAGAAGA 
oshIGF1R5_as: 
CGCGTAAAAACCATCAGGATTGAGAAGATCT
CTTGAATCTTCTCAATCCTGATGG 
oshIGF1R6_s: 
TCCCGCACCATCCTGAAGGGCAATTCAAGAG
ATTGCCCTTCAGGATGGTGCTTTTTA 
shIGF1R6 GCACCATCCTGAAGGGCAA 
 
oshIGF1R6_as: 
CGCGTAAAAAGCACCATCCTGAAGGGCAATC
TCTTGAATTGCCCTTCAGGATGGTGC 
 
Table 3: Tested shRNAs against IGF1R, sequences and oligonucleotides. Sense strands of used 
shRNAs were designed by the algorithm BLOCK-iT™ RNAi Designer (Invitrogen, Karlsruhe, Germany) 
and embedded into a standard shRNA structure to enable cloning of the shRNA by using oligonucleotides 
into the expression vector pINV-7 (TaconicArtemis), transcripts formation of hairpin structure and 
termination of Pol III transcription.  Sequences are displayed in 5´-3´direction and are designated “sense” 
when complementary to target mRNA. All oligonucleotides were purchased from metabion, Martinsried, 
Germany. 
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2.2.5 Cloning of expression vectors for two shRNAs (pshIGF1R2_shIR5 and 
pshIR5_shIGF1R2) 
For cloning of double KD Vectors MluI restriction site was abolished from the 
vectors pINV-7_shIR5 (144), bearing a shRNA directed against IR, and pshIGF1R2 by 
MluI digestion followed by blunting and religation. Vectors without MluI restriction site 
were designated as pshIR5_dMluI and pshIGF1R2_dMluI. For cloning of 
pshIR5_shIGF1R2 the 8703 bp fragment of NheI/SpeI digested pshIGF1R2 was ligated 
to the 450 bp fragment of NheI/SwaI digested pshIR5_dMluI. For cloning of 
pshIGF1R2_shIR5 the 8703 bp fragment of NheI/SpeI digested pINV-7_shIR5 (144) was 
ligated to the 450 bp fragment of NheI/SwaI digested pshIGF1R2_dMluI. 
 
 
2.2.6 RecE/RecT based (ET)-cloning 
The arms of homology of Col1a1 needed for targeting vectors were subcloned 
from bacterial artificial chromosomes (BACs) bearing strain RPCIB731P14208Q 
(imaGenes, Nottingham) using ET-cloning, as described by Muyrers et al.. Two vectors 
were generated containing 3´ and 5´arm of homology. To obtain each PCR product for 
transformation in BAC cells containing pSC101-BAD-gbaA-tet (193) two consecutive 
PCR reactions were performed. In the first PCR step the primer couples designated as 
“inside” with pACYC177 (193) as template were used. The reactions were performed in a 
total volume of 50 µl, containing 2 ng  pACYC177 (193), 0.5 µM of each “inside” primer, 
sense and antisense, 0.3 mM dNTP Mix, 2 mM MgSO4, 1 x PCR reaction buffer (HIFI) and 5 
U HIFI platinum Taq polymerase (Invitrogen, Karlsruhe, Germany). Standard PCR program 
starts with 5 min of denaturation at 95°C, followed by 25 cycles of denaturation at 95°C for 
30 sec, annealing at 58 °C for 30 sec and elongation at 72 °C for 2.5 min and a final 
elongation step at 72 °C for 10 min. PCR products were purified using QIAquick Gel 
Extractions-Kit (Qiagen, Hilden, Germany), according to manufacturer’s instructions for 
PCR-fragment purification. For elimination of template DNA products were digested 
with DpnI for at least 3 hours and subsequently purified using QIAquick Gel Extractions-
Kit (Qiagen, Hilden, Germany), as described under 2.2.1. The second PCR step was 
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performed using the primer couples designated as “outside” with 5 µl of the respective 
PCR product obtained from step one as template. Reaction mixture and PCR program 
were the same as described above for the first PCR step.   
Primer couples “inside” and “outside” used to gain PCR products for ET-cloning of 3´ 
arm of homology as well as 5´ arm of homology are stated in table 4. Prior to transfection 
PCR products were purified using MSB® Vario Cleanup Kit (Invitek, Berlin, Germany), 
following manufacturer´s protocol 2. Both arms of homology for targeting of Col1a1 
locus were subcloned from BAC to the vectors pCol1a1_3´arm, containing the 3´arm arm 
of homology, and pCol1a1_5´arm, containing the 5´arm of homology. 
 
Arm of 
homology 
Primer name Primer sequence (5´-3´) 
3´_s-inside AGGTGGGGAGAGGCCAGCTACCCCTCCATGTGTGACCAAG
GAGCAACCTGGCAATTGGAGTTTTCGTTCCACTGAGCGTC 
3´_as-inside GTCTACAGAGTGAGTTCCAGGACAGCCAGGGCTACACAGA
GAAACCCTGTCTCTGATCAATGCTCTGCCAGTGTTACAACC 
3´_s-outside TGTGACACCCCAGCATTAGAAGGCCCCTTCTATACTAAATT
ATGGTTTCTTTGGGCTAGAGGTGGGGAGAGGCCAGCTACC
CC 
3´arm 
3´_as-outside AATCCCAGCACTTGGGAGGCAGAGGCAGGCGGATTTCAGA
GTTTGAGGCCAGCCTGGTCTACAGAGTGAGTTCCAGGACA
G 
5´_s-inside GCCCTCAAAGGGATTCAAGCAGCAGAAACAGGGACTGAGA
CATGGAGGAGTTTAAACGCAATTGGAGTTTTCGTTCCACT 
5´_as-inside CAGCTTCATATGGCAGGACCTGCCTTCCCTGCAGAGCCCCA
CCTGAGCTTGCTGATCAATGCTCTGCCAGTGTTACAACC 
5´_s-outside TCTCCATGCTGACGACCTGAGGCCTGGGAGGTGTTGCCCAT
GGATCCTGGGAGGTTCATGAGCCCTCAAAGGGATTCAAG 
5´arm 
5´_as-outside GGGAGATGAACCAATGACACCTTCCCTCCCTCCTGGTCCCT
TGAACTTCCTGGGTCACCAGCTTCATATGGCAGGACCTGC 
 
Table 4: Primers used in ET-cloning.  Primers used in ET-cloning to gain arms of homology for targeting 
of Col1a1 locus. Primer couples designated as ”inside” are used for a  first PCR step with pACYC177 
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(193) as template. Primer couples designated as “outside”  are used for the second PCR step with the 
Product of step one as template. Primer sequences are displayed in 5´-3´direction. All primers were 
purchased from metabion, Martinsried, Germany.  
 
 
2.2.7 Cloning of pCol1a1T(RMCE_2Neo) 
The targeting vector, pCol1a1T(RMCE_2Neo), for insertion of RMCE_2Neo in 
the locus of Col1a1 was cloned in 25 steps, as described below. All oligonucletides used 
for cloning these vectors are stated in table 5. For cloning of the first intermediate 
pColT1.1 the 3371 bp fragment of XhoI/KpnI digested pBasic48 (TaconicArtemis, 
Cologne, Germany) was ligated to the annealed oligonucleotides oColT1.1_s and 
oColT1.1_as. SbfI digested pColT1.1 was ligated to the 1823 bp fragment of SbfI 
digested pINV-7 (TaconicArtemis, Cologne, Germany) to generate pColT1.2. For 
cloning of pColT1.3 the vector pBasic46 (TaconicArtemis, Cologne, Germany) was 
XhoI/KpnI digested and ligated to annealed oligonucleotides oColT1.3_s and 
oColT1.3_as to gain pColT1.3. The 3190 bp fragment of PstI/MluI digested pColT1.3 
was ligated to the 5562 bp fragment of PstI/AscI digested pCAGGS-I-lacZ-pA 
(TaconicArtemis, Cologne, Germany) to generate pColT1.4. pColT1.4 was Nhe/KpnI 
digested and the resulting 5629 bp fragment was ligated to the 5001 bp fragment of 
Nhe/KpnI digested pColT1.2 to give pColT1.5. For cloning of pColT2.1 the plasmid 
pBasic45 (TaconicArtemis) was XhoI/KpnI digested and ligated to the annealed 
oligonucleotides oColT2.1_s and oColT2.1_as. The vector was ClaI/NheI digested and 
the resulting 2719 bp fragment was ligated to the 1989 bp fragment of ClaI/NheI digested 
pTT84 (TaconicArtemis, Cologne, Germany) to gain pColT2.2. In the next step the 4697 
bp fragment XhoI/SalI digested pColT2.2 was ligated to the 4038 bp fragment of 
XhoI/SalI digested pTT71-hGH (TaconicArtemis, Cologne, Germany) to obtain 
pColT2.3. For cloning of pColT2.4 the plasmid pBasic45 (TaconicArtemis, Cologne, 
Germany) was BamHI/AflIII digested and ligated to the annealed oligonucleotides 
oColT2.4_s and oColT2.4_as. pColT2.4 was HpaI/FseI digested and ligated to the 2082 
bp fragment of BsaBI/FseI digested pTT84-new (TaconicArtemis, Cologne, Germany). 
pColT2.5 was generated by ligation of the 4782 bp fragment of AscI/AflIII digested 
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ColT2.4 to the 3536 bp fragment of AscI/AflIII digested pColT2.3. pColT2.5 was AscI 
digested and ligated to the 7496 bp fragment of AscI digested pColT1.5 to obtain 
pColT2.6. For cloning of the intermediate pColT3.1 the 2789 bp fragment of BsaBI/KpnI 
digested pBasic45 (TaconicArtemis, Cologne, Germany) was ligated to the annealed 
oligonucleotides oColT3.1_s and oColT3.1_as. pColT3.1 was EcoRI/KpnI digested and 
ligated to annealed oligonucleotides oColT3.2_s and oColT3.2_as to gain pColT3.2. The 
3000 bp fragment of SfiI/KpnI digested pColT3.2 was ligated to the 1051 bp fragment of 
SfiI/KpnI digested pINV-6 (TaconicArtemis, Cologne, Germany) to generate pColT3.3. 
pColT3.4 was obtained by ligation of NarI/MfeI digested pColT3.3 to 3870 fragment of 
BstBI/MfeI digested pCol1a1_3´arm. For cloning of pColT3.5 the 7898 bp fragment 
MluI of digested pColT3.4 was ligated to the 7496 bp  fragment of AscI digested 
pCol2.6. For cloning of pColT4.1 pBasic45 (TaconicArtemis, Cologne, Germany) was 
XhoI/KpnI digested and ligated to the annealed oligonucleotides oColT4.1_s and 
oColT4.1_as. pColT4.2 was generated by ligation of the 3165 bp fragment of PacI/KpnI 
digested pColT4.1 with the annealed oligonucleotides oColT4.2_s and oColT4.2_as. The 
3230 bp fragment of SfiI/FseI digested pColT4.2 was ligated to the 1051 bp fragment of 
SfiI/FseI digested pINV-6 (TaconicArtemis, Cologne, Germany) to generate pColT4.3.  
This plasmid was ClaI/NcoI digested and the resulting 4268 bp fragment was ligated to 
the 822 fragment of ClaI/NcoI digested pINV-7 (TaconicArtemis, Cologne, Germany) to 
gain pColT4.4. pColT4.5 was generated by T4 blunting the AscI restriction site of 
pColT4.4 and religation of the generated fragment. For cloning of pColT4.6 the vector 
pColT4.5 was MluI digested, the resulting fragment was blunted and ligated to the 1319 
bp fragment of SfiI/NdeI digested pINV-6 (TaconicArtemis, Cologne, Germany). 
pColT4.7 was obtained by ligation of PmeI/BclI digested pColT4.6 to 10441 bp fragment 
of PmeI/BclI digested pCol1a1_5´arm. For generating the final targeting vector 
pCol1a1T(RMCE_2Neo) pColT4.7 was MluI/BstBI digested and the resulting 13454 bp 
fragment was ligated to the 12509 bp fragment of AscI/BstBI digested ColT2.6.  
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oligonucleotide Sequence (5´-3´) 
oColT1.1_s TCGAGGCGCGCCAGTATAACTTCGTATAGCATACATTATACGAAGTTAT
AGTCCTGCAGGGCTAGCACGCGTGGTAC 
oColT1.1_as CACGCGTGCTAGCCCTGCAGGACTATAACTTCGTATAATGTATGCTATA
CGAAGTTATACTGGCGCGCC 
oColT1.3_s 
 
TCGAGGCTAGCAGATAACTTCGTATAGCATACATTATACGAAGTTATAG
TCTGCAGCTGACGCGTGGCGCGCCGGTAC 
oColT1.3_as CGGCGCGCCACGCGTCAGCTGCAGACTATAACTTCGTATAATGTATGCT
ATACGAAGTTATCTGCTAGCC 
oColT2.1_s 
 
GATCCGGCGCGCCGCTAGCACGTGATCGATACTCGAGGTACCGTCGACG
AATTCTTAAGTGTACA 
oColT2.1_as CATGTGTACACTTAAGAATTCGTCGACGGTACCTCGAGTATCGATCACG
TGCTAGCGGCGCGCCG 
oColT2.4_s 
 
GATCCCGCGGCCGCGAGCTCGTTTAAACGGCCGGCCACGTGGTTAACGG
CGCGCCATCGATA 
oColT2.4_as CATGTATCGATGGCGCGCCGTTAACCACGTGGCCGGCCGTTTAAACGAG
CTCGCGGCCGCGG 
oColT3.1_s 
 
TTCGAACCATGGCCCGGGCGGCGCCATGGCAATTGGCCATAGCGGCCTA
GGCCGGCCGAATTCGGTAC 
oColT3.1_as CGAATTCGGCCGGCCTAGGCCGCTATGGCCAATTGCCATGGCGCCGCCC
GGGCCATGGTTCGAA 
oColT3.2_s 
 
AATTCAGAAGTTCCTATTCCGAAGTTCCTATTCTTCAAAAGGTATAGGA
ACTTCTTAAGACGCGTCAGCTGGCGCGCCGGTAC 
oColT3.2_as CGGCGCGCCAGCTGACGCGTCTTAAGAAGTTCCTATACCTTTTGAAGAA
TAGGAACTTCGGAATAGGAACTTCTG 
oColT4.1_s 
 
TCGAGGTTTAAACGGCCATAGCGGCCTAGGCCGGCCATCGATTTAATTA
AGGTAC 
oColT4.1_as CTTAATTAAATCGATGGCCGGCCTAGGCCGCTATGGCCGTTTAAACC 
 
oColT4.2_s 
 
CTGATCAGTTAACGCGTGAAGTTCCTATACTTTCTAGAGAATAGGAACT
TCGGAATAGGAACTTCTCCATGGTTAAT 
oColT4.2_as TAACCATGGAGAAGTTCCTATTCCGAAGTTCCTATTCTCTAGAAAGTAT
AGGAACTTCACGCGTTAACTGATCAGGTAC 
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Table 5: Oligonucleotides used for cloning pCol1a1T(RMCE_2Neo). Corresponding sense and 
antisense oligonucleotides were phosphorylated and annealed as described under 2.2.2. All 
oligonucleotides were purchased from metabion, Martinsried, Germany. Sequences are displayed in 5´-
3´direction.  
 
 
2.2.8 Cloning of a basic exchange vector for RMCE-2 and pC-shIR5  
As an exchange vector for RMCE-2 a basic shRNA expression vector, pColEx5 
was cloned. All oligonucleotides used for cloning pColEx5 are stated in table 6. For 
cloning of the first intermediate pColEx1 the 2958 bp fragment of AscI/KpnI digested 
pBasic45 (TaconicArtemis, Cologne, Germany) was ligated to the annealed 
oligonucleotides oColEx1_s and oColEx1_as. pColEx1 was FseI/XhoI digested and the 
resulting 3029 bp fragment was ligated to a 1837 bp fragment resulting from FseI/XhoI 
digestion of pTT84 (TaconicArtemis, Cologne, Germany) to generate pEx2. AscI 
digested pINV-7 (TaconicArtemis, Cologne, Germany) was ligated to the annealed 
oligonucleotides oColEx2_s and oColEx2_as to yield pColEx3. pColEx3 was FseI 
digested and ligated to the annealed oligonucleotides oColEx4_s and oColEx4_as to  
obtain pColEx4. For cloning of the final exchange vector pColEx5 the 4846 bp fragment 
of FseI/AscI digested pColEx2 was ligated to the 3186 bp resulting from FseI/AscI 
digestion of pColEx4.  
 
oligonucleotide Sequence (5´-3´) 
oColEx1_s CGCGCCGGCCGGCCCTCGAGCGAAGTTCCTATACTTTCTAGAGAATAGG
AACTTCGGAATAGGAACTTCGGTAC 
 
oColEx1_as CGAAGTTCCTATTCCGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTC
GCTCGAGGGCCGGCCGG 
 
oColEx2_s  CGCGCCTAGGCTAGCCATGGTGATCA 
 
oColEx2_as CGCGTGATCACCATGGCTAGCCTAGG 
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oColEx4_s CCTAGGTACCATATGACCGG 
 
oColEx4_as TCATATGGTACCTAGGCCGG 
 
 
Table 6: Oligonucleotides used for cloning basic RMCE-2 exchange vector. Corresponding sense and 
antisense oligonucleotides were phosphorylated and annealed as described under 2.2.1.  All 
oligonucleotides were purchased from metabion, Martinsried, Germany. Sequences are displayed in 5´-
3´direction.  
 
 
The shRNA expression vector pColEx_shIR5 was generated by ligating BbsI/MluI 
digested pColEx5 to annealed oligonucleotides oshIR5_s and oshIR5_as (144). 
 
 
2.2.9 Cloning of pColVaLo_shEgln1 
The targeting vector, pColVaLo_shEgln1, for insertion of VaLo_shEgln1 in the 
locus of Col1a1 was cloned in 9 steps, as described below. All oligonucleotides used in 
this cloning procedure are stated in table 7. First the FseI site in pINV-7 
(TaconicArtemis, Cologne, Germany) was eliminated by digesting the vector with FseI, 
blunting the resulting fragment followed by its religation to gain pVaLo1. In a second 
step the NheI and SpeI sites in pVaLo1 were removed by digesting with both Enzymes 
and religation of the resulting 8669 bp fragment. The resulting vector pVaLo2 was 
KpnI/AscI digested and ligated to the annealed oligonucleotides oVaLo3_s and 
oVaLo3_as to gain pVaLo3. pVaLo3 was PspXI/SfiI digested and ligated to the annealed 
oligonucleotides oVaLo4_s and oVaLo4_as to generate pVaLo4. For cloning of pVaLo5, 
pVaLo4 was SpeI digested and ligated to the 1884 bp fragment of NheI digested 
pColT1.2. pVaLo6 was cloned by ligation of NheI/HpaI digested pVaLo5 with the 888 
bp fragment of XbaI/SwaI digested pINV-6 (TaconicArtemis, Cologne, Germany). 
pVaLo_shEgln1 was gained from ligation of MfeI/MluI digested pVaLo5 to the 412 bp 
fragment of MfeI/MluI digested pINV-7_shEgln1(TaconicArtemis, Cologne, Germany). 
The vector pCol_5´-3´arms was generated by ligation of PmeI/BclI digested 
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pCol1a1_3´arm with the 7141 bp fragment of PmeI/BclI digested pCol1a1_5´arm. The 
final vector pColVaLo_shEgln1 was cloned by ligation of FseI/MluI digested pCol_5´-
3´arms to the 7056 bp fragment of FseI/AscI digested pVaLo_shEgln1.  
 
 
oligonucleotide Sequence (5´-3´) 
oVaLo3_s CGCGTGGTACCGAATTCGTTAACGCTAGCGGCCGGCCATGTAC 
 
oVaLo3_as ACATGGCCGGCCGCTAGCGTTAACGAATTCGGTACCA 
 
oVaLo4_s TCGACATGGCGCGCCGCTCGAGGATCACGTGACTAGTGGCCATAG 
 
oVaLo4_as TGGCCACTAGTCACGTGATCCTCGAGCGGCGCGCCATGT 
 
 
Table 7: Oligonucleotides used for cloning pColVaLo_shEgln1. Corresponding sense and antisense 
oligonucleotides were phosphorylated and annealed as described under 2.2.1.  All oligonucleotides were 
purchased from metabion, Martinsried, Germany. Sequences are displayed in 5´-3´direction.  
 
 
2.2.10 Isolation of Genomic DNA 
To obtain genomic DNA from cultured cells murine embryonic stem cells were 
incubated in lysis buffer (10 mM Tris-HCl (pH 7.5), 10 mM EDTA, and 10 mM NaCl, 5% 
(w/v) N-Laurylsacrosinate, 0.5 mg/ml proteinase K) at 60°C overnight. DNA was 
precipitated by adding double amount of 100% ethanol, absolute, and incubation for 1 h at 
4°C. When performing DNA-isolation from 6-well cultured cells, DNA- precipitate was 
transferred into a new vial and washed twice with 70% (v/v) ethanol. After air drying at room 
temperature (RT) for 15 minutes, DNA was and resolved in 200 µl TE buffer (10 mM Tris- 
HCl (pH 7.5), 1 mM EDTA (pH 8.0)). When performing DNA-isolation from 96-well 
cultured cells, DNA- precipitate was washed and dissolved on 96-well plate. After 
precipitation liquid was discharged and DNA precipitate was washed twice with 70% (v/v) 
ethanol. After air drying at room temperature (RT) for 15 minutes DNA was directly resolved 
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in digest reaction mix for southern blot analysis. For genomic DNA isolation from mouse tail 
biopsies, samples were incubated overnight in lysis buffer (100 mM Tris-HCl (pH 8.5), 5 
mM EDTA, 0.2% (w/v) SDS, 0.2 M NaCl, 200 µg/ml proteinase K) in a thermomixer 
(Eppendorf, Hamburg, Germany) at 55°C and 1100 rpm. Samples were centrifuged to discard 
debris and supernatant was transferred into a new vial. DNA-precipitation was then 
performed by addition of an equivalent amount of isopropanol. After centrifugation and 
washing twice with 70% (v/v) ethanol, the DNA pellet was dried at room temperature for 15 
minutes and resolved in 400 µl in ddH2O. 
 
 
2.2.11Polymerase Chain Reaction (PCR) for genotyping of transgenic mice 
The PCR method (160, 161) was used to genotype generated mice for the presence of 
transgenic elements using customized primers listed in table 8. Reactions were performed in 
a thermocycler MultiCycler PTC 225 Tetrad (Bio-Rad Laboratories, CA, USA). All PCRs 
were performed in a total volume of 50 µl, containing a minimum of 50 ng genomic template 
DNA, 0.5 µM of each primer, sense and antisense, 0.3 mM dNTP Mix, 2 mM MgCl2, 1 x 
PCR buffer and 5 units/µl Taq DNA Polymerase (Invitrogen, Karlsruhe, Germany). Standard 
PCR program starts with 5 minutes (min) of denaturation at 95°C, followed by 35 cycles of 
denaturation at 95°C for 30 seconds (sec), annealing at 56 °C for 30 sec and elongation at 
72°C for 1 min and a final elongation step at 72°C for 10 min. Amplified DNA fragments 
were detected via electrophoretic separation in agarose gel (1,,5 % (w/v), agarose; 1 x TAE; 
0.5 mg/ml ethidium bromide; 1 x TAE electrophoresis buffer). Expected amplicon sizes are 
listed in table 8. 
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Detected alleles  Primer  Amplicons 
 
1165_s: 
CCATGGAATTCGAACGCTGACGTC 
 
 
- R26(shIGF1R1-6) 
 
- R26(shIR5) 
 
- Col1a1(VaLo_shEgln1) 
 
 
1165_as: 
TATGGGCTATGAACTAATGACCC 
 
 
Targeted allele: 365 bp 
 
Wt allele: no amplicon 
 
1734_s:  
GTTGGGTCCACTCAGTAGATGCC 
 
 
- R26(shIR5_shIGF1R2) 
 
1734_as: 
GGAACATACGTCATTATTGACGTC 
 
 
Targeted allele: 1050 bp 
 
Wt allele: no amplicon 
 
Table 8: Primer used in genotyping and amplicon length. Transgenic mice were genotyped via PCR. 
Primers used for amplification and the expected amplicon sizes for targeted alleles are shown. Primer 
sequences are displayed in 5´-3´direction and are designated “sense” when coinciding with transcriptional 
direction. All primers were purchased from metabion, Martinsried, Germany.  
 
 
2.2.12 Southern Blotting 
Southern Blots were used to detect targeting of Cola1 locus, Cre-mediated 
deletion of the neomycin resistance gene from Col1a1(RMCE_2Neo) as well as RMCE-
integration in Cola1(RMCE) and R26(RMCE). Probes and enzymes used for the 
particular detections are listed in table 9. 10 µg of genomic DNA were digested overnight 
using 40 U of enzyme, respectively to the detection to be performed. After separating 
fragments by size via electrophoresis in a 0.8 % (w/v) agarose gel at 90 V DNA was 
transferred to a HybondTM –XL nylon membrane (GE Healthcare, Freiburg Germany) by 
alkaline capillary transfer (194). Blotted DNA was crosslinked to the membrane by 
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baking at 80 °C for 1 h after washing two times  with 2x SSC. Membrane was pre-
hybridized in hybridization solution (1 M NaCl, 50 mM Tris-HCl (pH 7.5), 10 % (w/v) 
dextran sulfat, 0.1 % (w/v) SDS, 250 µg/ml sonicated salmon sperm) at 65 °C overnight 
in rotating hybridization tubes. Probes were generated by PCR or by digestion of plasmid 
DNA as stated in table 9 and labelled with α- 32P-dCTP (PerkinElmer Life Science, 
Cologne, Germany) using Amersham Readyprime II Random Prime Labelling System 
(GE Healthcare, Freiburg Germany) following users manual. For hybridization labelled 
probes were added to pre-hybridization solution and incubated overnight at 65 °C in 
rotating hybridization tubes. Unspecifically bound probes were removed by washing 
hybridizes membrane initially twice with 2 x SSC/ 0.1 % (w/v) SDS under gentle shaking 
for 10-20 min, followed by one washing step in 0.2 x SSC/ 0.1 % (w/v) SDS until 
radiation of membrane is reduced to a value under 20 impulses per second (IPS). Washed 
membranes were sealed with plastic foil and exposed to autoradiography film Kodak 
BioMax MS; Sigma Aldrich, Deisenhof, Germany) at -80 °C for 3 days. Films were 
developed using automatic developer processing machine Curix60 (Agfa Health Care 
GmbH, Mortsel, Belgium).  
 
Probe Size Origin 
Rosa3´ 386 bp Digest of vector JS43 (TaconicArtemis, Cologne, Germany) with HindIII 
 
Rosa5´ 533 bp PCR on vector JS32 (TaconicArtemis, Cologne, Germany) using R62s 
(AAGGATACTGGGGCATACG) and R64as 
(CTTCTCAGCTACCTTTACACACC) 
 
internal_Neo 519 bp Digest of vector KD602 (TaconicArtemis, Cologne, Germany) with HindIII 
and EcoRI 
 
internal_Puro 292 bp Digest of vector pMultilink  
Puro (TaconicArtemis, Cologne, Germany) with SpeI and XhoI 
 
Col3´ 451 bp PCR on BAC (RPCIB731P14208Q, imaGenes, Nottingham) using 
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ocol11(GGTCAGGATCTGACAGGTC) and  
ocol12 (GTCAGGGAGTGTCTCATCTGGC)  
 
Col 5´ 346 bp PCR on BAC (RPCIB731P14208Q, imaGenes, Nottingham, UK) 
using Cola 5´_s (CCTCTTGCTGCTGCTCCCTCC) and Cola 5´_as 
(CCACCGTTATAGACCTACTCTTC)  
 
Table 9: Probes used in Southern Blot analysis. Probes used for validation of RMCE integrations in 
R26(RMCE), Cola1(RMCE-2), for targeting of Cola1 locus with Col1a1(RMCE-2Neo), Cre-mediated 
deletion of Neo from Col1a1(RMCE-2Neo) and targeting of Cola1 locus with Col1a1(VaLo_shEgln1). 
Primer sequences are displayed in 5´-3´direction. All primers were purchased from metabion, Martinsried, 
Germany. 
 
 
2.2.13 RNA Extraction and Quantitative Realtime-PCR (qPCR) 
Realtime-PCR was applied to determine mRNA levels of IR, IGF1R and Egln1. 
Total RNA was extracted from murine ES-cells and tissue samples using Qiagen RNeasy 
Plus Mini Kit (Qiagen, Hilden, Germany) according to manufacturer´s introductions. 1 
µg mRNA per sample was reversely transcribed using High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Darmstadt, Germany) following users manual. 
Quantification was performed by using gene specific TaqMan® Gene Expression Assays 
(Applied Biosystems, Darmstadt, Germany) and ABI Prism 7900HTFast real-time PCR 
System (Applied Biosystems, Darmstadt, Germany).Gene Expression Assays and 
Accession Numbers of the National Centre of Biotechnology Information (NCBI) used 
for assay selection are stated in table 10. Samples were adjusted for total RNA content to 
levels of heterochromatin protein 1 binding protein 3 (Hp1bp3). Relative cDNA amounts 
were quantified using Sequence Detector System (SDS) software version 2.1 (ABI). 
Threshold cycle (Ct) values were automatically converted to fold range RQ value ((RQ) 
= 2-∆∆Ct).  
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mRNA Accession Number of reference 
sequence 
Assay 
IGF1R 
 
NM_010513.2 Mm00802831_m1 
IR 
 
NM_010568.2 Mm01211881_m1 
Egln1 
 
NM_053207.2 
 
Mm00459770_m1 
 
tetR 
 
DQ_414432 
 
Mm01211881_m1 
 
Hp1bp3 
 
NM_010470.1 
 
Mm00802807_m1 
 
Table 10: TaqMan® Gene Expression Assays and NCBI – Accession Numbers. Assays used for 
quantification of IGF1R, IR and Hp1bp3 mRNA levels were purchased from Applied Biosystems, 
Darmstadt, Germany.  
 
 
2.2.14 DNA-Sequencing 
DNA-sequencing reactions were performed used Big Dye Termination v3.1 Cycle 
Sequencing System Kits (Applied Biosystems, Darmstadt, Germany). 400 ng DNA were 
used in a reaction mix containing 1.0 µl, 2.5 x Ready Reaction Premix (2.5x), 3.0 µl 5 x 
BigDye, Sequencing Buffer, 2.0 pmol/µl sense as well as antisense primer in a total 
volume of 10 µl. Amplification was performed following the program of 20 sec at 95 °C, 
20 sec at 55 °C, 2 min at 60 °C for 25 cycles. Fluorescent-labelled fragment were purified 
by using Sephadex TM G-50 Medium (GE Healthcare Bio-science, Freiburg, Germany). 
DNA- sequence was automatically determined using ABI Prism 3130xl genetic Analyser. 
Evaluation of sequencing data was performed using Sequencher 4.9 (Gene Codes 
Corporation, Ann Arbor, USA) software. 
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2.2.15 DNA and RNA Quantification 
Nucleic acid concentrations were determined by measurement of absorption at 
260 nm using NanoDrop® ND-1000 UV-Vis Spectrometer (Peqlab, Erlangen, Germany). 
Quality of purified nucleic acid was estimated by 260/280 nm absorbance ratio. 
 
 
2.3 Biochemistry 
 
2.3.1 Protein Extraction  
Total Protein was extracted from snap-frozen tissue samples. Tissues were 
disrupted in 3 ml lysis buffer (50mM HEPES (pH 7.4); 1% Triton X-100 (v/v); 50 mM 
NaCl; 10mM EDTA; 0.1% (w/v) SDS; Protease Inhibitor Cocktail Tablets mini (Roche 
Diagnostic, Mannheim, Germany), 1 tablet to 10ml; phosphataseinhibitorcocktail1 
(Roche Diagnostic, Mannheim, Germany)100µl to 10ml) per mg sample and 
homogenized using TissueLyser II (Qiagen, Hilden, Germany) for 2 min at 30 Hz with 5 
mm stainless steel beads (Qiagen, Hilden, Germany).  Cell debris were removed by 
centrifugation at 13.000 rpm for 1 h at 4 °C. Lysed adipose tissues were centrifuged twice 
to get rid of formed fat layer. Supernatant was transferred to fresh vial.  
 
 
2.3.2 Protein Quantification 
Protein concentrations were determined using bicinchoninic acid (BCA) protein 
assay using Pierce BCA protein assay kit (Fisher Scientific, Schwerte, Germany) 
following manufacturer´s protocol.  
 
 
2.3.3 Western Blotting 
Protein extracts were diluted to a concentration of 2.5 mg/ml in organ lysis and 4 
x SDS sample buffer (250 mM Tris-HCl (pH 6.8), 200 mM DTT, 8% (w/v) SDS, 40% 
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(v/v) glycerol, and 0.04% (w/v) bromophenol blue), incubated for a minimum time of 5 
min at 95 °C. Samples were stored at -80 °C when not used immediately. 
Protein extracts were separated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) on 4-12 % Novex® Tris-Glycine polyacrylamide gel 
(Invitrogen, Karlsruhe, Germany) in 1 x SDS running buffer. 50 -100 µg protein of each 
sample were applied to SDS gel. Unraveled protein were transferred to nitrocellose 
membranes (Invitrogen, Karlsruhe, Germany) using the iBlot® Dry Blotting System 
(Invitrogen, Karlsruhe, Germany). Membranes were blocked by incubating in 5 % (w/v) 
BSA in 1 x TBS, 0.1 % (v/v) Tween20 for 1 h rotating at room temperature. Target 
protein specific primary antibody were applied to the membrane in freshly prepared 
blocking solution, diluted as stated by manufacturer, and incubated overnight at 4 °C on a 
rotating device. After hybridization membranes were washed three times with 1 x 
TBS/0.01% (v/v) Tween20 for 5 min. Hybridization and washing procedure was repeated 
with Anti rabbit IG-HRP linked #7074 (Cell signaling Technology, Beverly, USA), used 
as secondary antibody. Membranes were incubated in ECL Western Blotting Substrate 
(VWR International, Langenfeld, Germany) for 15 min, sealed with plastic foil and 
exposed to chemiluminescence films (Kodak BioMax MS; Sigma-Aldrich Chemie 
GmbH, Deisenhof, Germany) and  developed using an automatic developer processing 
machine Curix60 (Agfa Health Care GmbH, Mortsel, Belgium). For adjustment to total 
protein levels membranes were stripped by Incubating for 0.5-1 h at 56 °C in stripping 
buffer (100mM Mercaptoethanol, 2 % SDS and 62.5 mM Tris-HCl at pH 6.7) and 
blotting procedure was repeated with α-tubulin (DMA1) mouse mAb #3873 (Cell 
signaling Technology, Beverly, USA) in case of IR and IGF1R detection. Phospho-Akt 
and Phospho-GSK3 levels were adjusted to total Akt or total GSK3 levels, respectively. 
Used Antibodies are displayed below in table 11. 
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Target protein Antibody 
IGF1R 
 
IGF-I Receptor β (111A9) Rabbit mAb #3018 
 
IR 
 
Insulin Receptor β (4B8) Rabbit mAb #3025 
 
α-tubulin α-Tubulin (DM1A) Mouse mAb #3873 
 
Phospho-Akt  Phospho-Akt (Ser473) Antibody #9271 
 
Total Akt Akt (pan) (11E7) Rabbit mAb #4685 
 
Phospho-GSK3 
 
Phospho-GSK-3β (Ser9) (5B3) Rabbit mAb #9323 
 
Total GSK3 GSK-3β (27C10) Rabbit mAb #9315 
 
 
Table 11: Antibodies used for Western blot. Antibodies used for detection of IGF1R and IR expression 
levels as well as for the phosphorylation status of Akt and GSK3. All antibodies were purchased from Cell 
Signalling Technology, Beverly, USA. 
 
 
2.3.4 Enzyme-linked Immunosorbent Assay (ELISA) 
Serum Insulin levels were determined using Rat insulin ELISA Kit, #90010 
(Crystal Chem., Downer Grove, IL, USA) and Mouse Insulin Standard 2ng # 90020 / 
INSSM021(Crystal Chem., Downer Grove, IL, USA), according to manufacturer´s 
guidelines. Serum IGF1 concentrations were detected using Quantikine Mouse/Rat IGF-I 
Immunoassay # MG100 (R&D systems, Wiesbaden, Germany) 
 
 
2.3.5 Histological analysis 
Pancreatic tissue samples were dissected, fixed overnight in 4% (w/v) PFA 
(Sigma Aldrich, Steinheim, Germany) and subsequently embedded for paraffin sections. 
Sections of 7 µm were deparaffinised and stained in hematoxylin and eosin. H&E (Sigma 
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Aldrich, Steinheim, Germany) staining was performed following standard protocols. 
Optical examination was performed using AxioVisio 4.2 (Carl Zeiss MicroImagin, 
Oberkochen, Germany) 
 
 
2.4 Cell culture 
 
2.4.1 Murine embryonic stem cell lines  
Embryonic stem cell lines used in this thesis are C57BL/6NTac(TaconicArtemis, 
Cologne, Germany), a Taconic substrain of C57BL/6 hybrid line and B6/RMCE 
(TaconicArtemis, Cologne, Germany) C57BL/6NTac implying the previously described 
RMCE system at the R26 locus (Fig. 5) including zsGreen, and promoter hygromycin 
resistance gene. 
 
 
2.4.2 Embryonic stem cell culture 
Murine Es stem cells were cultured on a layer of mitomycin C treated 
primary feeder fibroblasts. Dulbecco's Modified Eagle Medium (DMEM) containing 
20% fetal calf serum (FCS), 1 x non essential amino acids (MEM), 2 mM L-glutamine, 1 
mM sodium pyruvate, 20 mM HEPES (pH 7.4), 0.1 mM 2-β-mercaptoethanol, 2000 
U/ml LIF was used as culture medium. In case of the cell line B6/RMCE 
(TaconicArtemis) 150 µg/ml hygromycin was added to the medium whilst C57BL/6NTac 
(TaconicArtemis) cells were cultured without addition of antibiotics. ES cells were grown 
in 10 cm dishes, 6-well or 96-well culture plates (Falcon, Bedford, USA) and kept at 37 
°C under humid atmosphere (95 %) with 7.5 % CO2. ES cell colonies were splitted every 
1-3 days. Culture plates were washed once with PBS and treated with trypsin at 37°C 
until cells detached from the plate surface. Cells were resuspended in an appropriate 
volume of media and splitted (usually 1:3 – 1:6) onto fresh feeder dishes.  
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For long term storage ES-cells were frozen in cryovials (Nunc, Wiesbaden, Germany) 
with 10% DMSO at -80°C and transferred into liquid nitrogen. 
 
 
2.4.3 Transfection of ES cells with RMCE exchange vectors 
2 x 105 ES cells were plated on a 6 well plate one day before transfection. For 
formation of transfection complex 6 µl Fugene6 Transfection Reagent was mixed with 
100 µl serum free medium optiMEM I with Glutamax-I and incubated for 5 min at room 
temperature. 2 µg of circular exchange vector DNA (c=0.5 µg/µl) and 2 µg (c=0.5µg/µl) 
pCAGGS-flpe-ires-puro (125, 177) were added to 100 µl of the Fugene6/OptiMEM 
mixture and incubated for 45 min at room temperature. Subsequently this mixture was 
added drop wise to the medium of cultured cells and mixed by gentle circuiting 
movement. Medium of the transfected cells was changed one day after transfection. For 
simultaneous transfection of RMCE exchange vectors of R26 and Col1a1 RMCE systems 
same amount of each vector was used, as described above. From day 2 on, the medium 
was changed daily to medium containing either 200 µg/ml Geneticin (G418) after 
transfection with R26 exchange vectors, 1.5 µg/ml puromycin after transfection with 
Cola1 exchange vectors, or both antibiotics in same concentrations after transfection with 
exchange vectors of both RMCE-systems. Seven days after transfection, single clones 
were isolated by standard procedures as described (125, 178). Correct integration was 
subsequently validated by Southern Blot analysis. 
 
 
2.4.4 Electroporation of ES cells with targeting vectors  
For integration via homologues integration 100 µg of targeting vector were 
linearised by digestion with a single cutting restriction endonuclease in a total volume of 
400 µl. Subsequently linearized vector DNA was purified by phenol-chloroform 
extraction. Reaction solution was mixed well with 400 µl Phenol-chloroform-
isoamylalcohol, 25:24:1 in a Phase-Lock tube (5 Prime, Hamburg, Germany) and 
centrifuged for 5 min at 10.000 rpm. Supernatant was mixed with 400 µl chloroform-
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isoamylalcohol, 24:1 in a new Phase-Lock tube (5 Prime, Hamburg, Germany) and 
centrifuged as described above. 1/10 Volume NaOAc pH 5.2 and 2 Volumes of Ethanol 
absolute were added to the supernatant and centrifuge at 13.000 rpm for 30 min at  room 
temperature. DNA-pellet was washed in 1 ml 70% Ethanol, air dried and redissolved in 
TE buffer to a final concentration of 1ug/µl. 1x107 PBS washed cells were resuspended in 
700 µl Transfection buffer (20 mM HEPES (pH 7.0), 137 mM NaCl, 15 mM KCl, 0.7 
mM Na2HPO4, 6mM Glucose, 0.1mM β- mercaptoethanol) and transferred to 30 µg 
linearized targeting vector DNA in a volume of 100 µl. This suspension was incubated 
for 5 min at room temperature in an electroporation cuvette (Biorad, Hercules, USA), 
prior to electroporation cells in a Biorad Gene Pulser (Biorad, Hercules, USA) at 500 µF 
and 240 V. Time constant values in the range of 6.0 - 8.0 ms were accepted. After 
incubating the electroporated cells for 5 min at room temperature suspension was 
transferred to 3.5 ml prewarmed Dulbecco's Modified Eagle Medium (DMEM) 
containing 20% fetal calf serum (FCS), 1 x non essential amino acids (MEM), 2 mM L-
glutamine, 1 mM sodium pyruvate, 20 mM HEPES, 0.1 mM β-mercaptoethanol, 2000 
U/ml LIF and 2.5x106 (1 ml) cells were plated per 10 cm dish containing selection 
resistant feeder. Cells were cultured for 48 hours before start of selection with 200 µg/ml 
geneticin (G418) after electroporation with VaLo_shEgln1 and Col1a1(RMCE-2Neo) 
constructs 
 
 
2.4.5 Doxycycline (dox) treatment of ES cells 
Single ES cell clones were cultivated in ES cell medium, as described under 2.4.2, 
containing 1 µg/ml doxycycline (Sigma Aldrich, Steinheim, Germany) for 72 hours. 
 
 
2.4.6 Cre- mediated in virto deletion 
Floxed neomycin resistance gene was deleted from Col1a1(RMCE-2Neo) bearing 
cells by Cre-mediated in vitro deletion. Cre expression vector pHW1 (TaconicArtemis, 
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Cologne, Germany) was transfected by electroporation in circular form after purification 
by phenol-chloroform extraction as described under 2.4.3. 20 µg purified expression 
vector DNA were electroporated to 5x106 PBS washed cells using Amaxa Cell Line 
NucleofectorTM KitR (Amaxa Biosystems, Cologne, Germany) following users manuals 
protocol A13. Total cells were plated on 10 cm dish containing selection resistant feeder. 
Cells were trypsinized one day after electroporation and 1x103 to 1x104 Cells were plated 
on 10 cm dish containing selection resistant feeder. Cells were incubated for 7 days 
selecting with 150 µg/ml hygromycin. 
 
 
2.5 Mouse experiments 
 
2.5.1 Animal care 
General animal handling was performed as described by Hogan and Silver (167, 
168). Mice were kept in a pathogen free facility at TaconicArtemis GmbH, Cologne, 
Germany in isolated ventilated cages TecniplastTM (Tecniplast Deutschland GmbH, 
Hohenpeißenberg, Germany) providing a High-Efficiency Particulate Air (HEPA) filter 
supply (Tecniplast Deutschland GmbH, Germany) and exhaust air (99.97 %). Mice were 
housed at 21°C +/- 1°C on a 12 h light / 12 h dark cycle with the light on from 7 a.m. to 7 
p.m. Animals were fed ad libitum with Ssniff PS M-Z; S8289-Po12 (Ssniff Spezialdiäten 
GmbH, Soest, Germany) either as normal chow or with addition of 1 g/kg dox, for dox-
induction. Withdrawn of food was only required prior accomplishment of glucose 
tolerance test for 16 h. All animals had access to water ad libitum. At the end of the study 
period, animals were sacrificed by CO2 anaesthesia or cervical dislocation. All work was 
performed in accordance with the “Gesetz zur Regelung der Gentechnik” (GenTGS) 
October 2001 (German Biologic Act) and the Tierschutzgesetz 1998 (German Animal 
Welfare Act). Animal procedures and euthanasia were approved by the local government 
authorities (Bezirksregierung Köln) and were in accordance with National Institutes of 
Health guidelines. 
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2.5.2 Generation of transgenic mice 
C57BL/6NTac mouse strains were obtained from Taconic. Chimeric mice were 
generated at TaconicArtemis GmbH by injection of trypsinized recombinant ES cell 
clones into diploid blastocystes and implanted into the uterus of pseudopregnant mice. 
Male chimeras were mated to C57BL/6NTac females to gain fully derived ES mice.  
 
 
2.5.3 Body weight 
Body weight was monitored daily from the first day of dox-induction for one 
week and subsequently in weekly interval for 7 more weeks. 
 
 
2.5.4 Blood collection for determination of blood glucose levels and recovery of 
Serum 
Whole venous blood was collected daily 2 h after beginning of light phase from 
the first day of Dox-induction for one week and subsequently in weekly interval for 7 
more weeks by submandibular puncture of the vena facialis. Volumes of taken blood 
samples were 20 µl in daily and up to 100 µl in weekly collections. Fasted blood glucose 
values were measured using an automatic glucose monitor (Ascensia ELITE, Bayer Vital, 
Leverkusen, Germany). Serum was obtained after incubating blood for 30 min on ice and 
precipitation of cellular blood components by centrifugation for 15 min, at 13.000 rpm 
and 4°C.   
 
 
2.5.5 Glucose and insulin tolerance test 
For glucose tolerance tests (GTT), mice were fasted by withdraw of food 
overnight for 16 h. After determination of fasted blood glucose levels, each animal 
received 10 ml/kg body weight of 20 % glucose solution applied via an intraperitoneal 
injection. Blood glucose was determined in whole venous blood obtained after tail cut at 
15, 30, 60 and 120 min after injection.  
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Insulin tolerance tests (ITT) was performed in random fed animal injected 
intraperitoneal with a 0.75 U/ml insulin solution (0.75 U/kg body weight) after 
determination of random fed blood glucose concentration. Blood glucose levels were 
estimated as described above 15, 30 and 60 min after injection. 
 
 
2.5.6 Food intake 
Daily food intake was measured over a period of 7 days for mice in groups of up 
to 2 animals per cage and calculated as the average intake per mice and day of chow over 
the time stated. 
 
 
2.5.7 In vivo nuclear magnetic resonance measurement of fat content 
Whole body fat content was determined in vivo by nuclear magnetic resonance 
using Minispec mq7.5 NMR analyzer (Brucker Optics, Ettlingen, Germany). Whole body 
fat mass is obtained as percentage of bodyweight. 
 
 
2.5.8 Stimulation of Insulin cascade 
For detection of Stimulation of Insulin cascade mice were fasted for 6 h and 
received 0.75 U/ml insulin solution (0.75 U/kg body weight) via intraperitoneal injection 
30 min prior to dissection of tissue samples. Phosphorylation status of Akt at Ser473 and 
GSK3 at Ser9 was detected using Western blot. 
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2.6 Statistical Methods 
 
2.6.1 Standard Deviation 
Variability within data sets was estimated by their calculating standard deviation 
(σ). 
 
 
∑
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2.6.2 Two-Tailed Unpaired Students T Test 
Data sets were analyzed for statistical significance using a two-tailed unpaired 
student’s T test.  
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p values where taken from tables of t-distribution comparing values of T to tn1+n2 -2 
distribution. All p values below 0.05 were considered to be significant. 
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2.6.3 Analysis of variance (ANOVA) and Bonferroni post-test 
Analysis of variance (ANOVA) and Bonferroni post-test were calculated using 
GraphPad Prism Version 4.0 by GraphPad Software Inc. 
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3 Results 
 
3.1 Technical Development  
 
3.1.1 Screen for efficient shRNAs directed against IGF1R 
Two different strategies were tested for the simultaneous silencing of two target 
genes in transgenic mice. The first strategy is based on the generation of a murine ES cell 
line bearing two independent RMCE acceptor cassettes at distinct genomic loci. Such a 
cell line enables the specific integration of two different shRNA expression cassettes at 
the prepared RMCE alleles. As a second strategy, two shRNA expression units were 
combined in a single exchange cassette for integration into the R26 RMCE allele. 
After evaluation, the method was applied for the generation of a mouse model providing 
the concurrent KD of the insulin and the IGF1 receptor. For silencing of IR, a previously 
described shRNA (shIR5) was used. Strong KD triggered by shIR5 has been 
demonstrated in ES cells as well as in vivo (126, 179). An shRNA sequence for efficient 
and specific silencing of IGF1R needed to be identified. 
For silencing of IR a previously described shRNA (shIR5) was used. Strong KD 
triggered by shIR5 has been demonstrated in ES cells as well as in vivo (126, 179). To 
define a potent trigger for silencing of IGF1R, six shRNAs of different sequence were 
designed using the invitrogen algorithm BLOCK-iT™ RNAi Designer. Those were 
inserted into R26 RMCE exchange vectors for shRNA expression, yielding pR-
shIGF1R1 to pR-shIGF1R6. Single copies of each vector were stably integrated into the 
murine ES cell line B6/RMCE by employing the R26 RMCE system (126). Correct 
RMCE was confirmed by Southern blot analysis (Fig. 6A). Expected signal sizes are 4.3 
kb for R26 wt allele, 3.8 kb for R26(RMCE) allele before exchange and 6.2 kb for 
R26(RMCE) allele after exchange. The employed shRNA expression system allows tet-
repressor (tetR)-mediated temporal control of RNAi. Transcription of the shRNA is 
blocked in absence of dox by binding of co-expressed tetR to the tet-operator (tetO), 
inserted in H1tetO (Fig. 6B). Upon administration of dox tetR detaches from H1tetO and 
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allows Pol III-dependent transcription of the encoded shRNA (Fig. 6C). Efficiency of 
IGF1R silencing was analyzed in ES cells via qPCR after doxycyclin induction in two 
clones per shRNA (Fig. 6D). Values are displayed as percentage of IGF1R expression in 
untreated cells of each clone. KD efficiencies were ranging between 13 % and about 50 
% remaining IGF1R mRNA levels, as average of both clones. The most potent effect was 
observed for shIGF1R2 at 13 % residual IGF1R expression, which was therefore selected 
for further procedure. 
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Fig. 6: Screen for efficient shRNAs against IGF1R. Six shRNAs, shIGF1R1 to shIGF1R6, were tested 
for their KD efficiency in murine ES cells. Single copies of shRNA expression vectors, pR-shIGF1R1 to 
pR-shIGF1R6 were stably integrated in B6/RMCE employing the  R26 based RMCE system. A) Southern 
blot was used to control 3 clones per vector for correct integration. Expected sizes for R26 wt allele, 
R26(RMCE) allele before and after exchanged were 4.3 kb, 3.8 kb and 6.2 kb, respectively. The used 
shRNA expression system allowed tetR-mediated temporal control of RNAi, depicted in a schematic view. 
B) Transcription is blocked in the absence of dox by binding of the co-expressed tetR to H1tetO. C) Upon 
administration of dox tetR detaches from the promoter allowing transcription of the shRNA. D) mRNA 
expression rates of IGF1R were measured under conditions of induced (+dox, light grey bars) and not 
induced (-dox, white bars) shRNA expression in duplicates of two clone per shRNA. Induced (+dox, dark 
grey bar) and not induced (-dox, black bars) B6/RMCE cells were applied as negative control. Expression 
in not induced cells was set as 100 % for each clone. Values are mean ± SEM. 
 
 
3.1.2 Generation of murine ES cell line bearing two RMCE alleles (first strategy) 
This strategy is based on the generation of a murine ES cell line harbouring two 
alleles prepared for RMCE integration, to allow the simultaneous and specific integration 
of two inserts via cassette exchange, hereafter designated as double RMCE (dRMCE). 
A established singular RMCE system, mediating integration into the in the Rosa 26 locus, 
served as a technical basis for this approach (125).  
 As a first step a second RMCE system (RMCE-2) had to be designed, whose 
architecture rules out interactions with the R26 system to allow the employment of both 
approaches in one cell line. RMCE-2 was designed by example of the R26 RMCE system 
in terms of the used RMCE-strategy, recombinase and marker-system. Functionality of 
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RMCE-2 is based on FLP mediated recombination of two pairs of FRT and F5 sites. The 
employed F5 site is a functional FRT mutant displaying no interaction to FRT and F3 
sites (168). A β-galactosidase gene (lacZ) in the acceptor cassette allows verification of 
cells bearing a prepared RMCE-2 locus by β-galactosidase staining. Permanent antibiotic 
selection had to be omitted because the three resistance markers, well established for the 
adopted cell line, are elsewhere used in R26 RMCE and RMCE-2. In presence of Flp 
recombinase donor and acceptor cassette are exchanged between vector and genome 
through recombination of FRT and F5 pairs (Fig. 7C). Correct recombination of the FRT 
site sets a truncated, non functional, puromycin resistance gene (5´dPuro) in the donor 
cassette into the frame of an ATG at the genomic RMCE-2 site and facilitates it’s 
expression by employing a PGK-promoter. Transcription of 5´ dPuro after unspecific 
integration events is blocked by a polyadenylation signal (pA) in the exchange vector. 
Thus, clones positive for exchange in RMCE-2 can be selected by puromycin treatment 
of transfected cells.  
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Fig. 7: Functionality of RMCE-2 system. A) The RMCE-2 exchange vector carries following features in 
5´-3´direction: polyadenylation signal (pA), FRT site, puromycin resistance gene leaking start codon and 
promoter (5´dPuro), insert, F5 site. B) The genomic part of RMCE-2 is composed of following elements in 
5´-3´direction: phospoglyceratkinase-promoter (PGK), start codon (ATG), FRT site, CAGGS promoter 
driven β-galactosidase gene (lacZ), F5 site. C) Cassette exchange is mediated through double reciprocal 
recombination of both pairs of FRT and F5 sites. Functionality of 5´dPuro is reconstituted through RMCE 
reaction, selection of positive clones can be carried out by puromycin treatment. D) RMCE-2 was designed 
to act independently from the R26 based system to allow the simultaneous use of both systems. Expression 
of both selection markers is exclusively given by correct integration of RMCE-2 cassette in RMCE-2 locus 
and correct exchange between R26 RMCE donor and acceptor cassette.  Specificity between R26 RMCE 
and RMCE-2 is achieved by the choice of the utilized recognition sites and the architecture of marker 
systems exclusively activated by specific exchange. 
 
 
To allow the combined application of RMCE-2 and R26 RMCE systems in one 
cell line, interactions between both systems had to be turned out by their architecture. 
Incompatibility between RMCE-2 and R26 RMCE systems is obtained through the 
choice and order of recombination sites and arrangement of selection systems.  
The RMCE-2 system employs couples of FRT and F5 sites whilst the R26 RMCE system 
uses FRT and F3 pairs, making cassette exchange through double reciprocal 
recombination specific for each associated couple of acceptor and donor cassette. 
Furthermore, architecture of the marker systems affords antibiotic selection after specific 
exchange in both RMCE loci. Reconstitution of the selection marker in RMCE-2 depends 
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on the correct recombination of the FRT site, whereas it depends on recombination of the 
F3 site in the R26 system. Since FRT and F3 sites are part of the reading frame of the 
accordant resistance genes activation of those is exclusively given by exchange of R26 
RMCE donor and acceptor cassette and RMCE-2 donor and acceptor cassette. RMCE-2 
was designed to act independently from R26 RMCE. Using both systems in one ES cells 
line should afford the specific exchange in both systems. Cells bearing both RMCE loci 
exchanged correctly can be selected by concurrent treatment with both antibiotics, 
puromycin and geneticin (G418) (Fig. 7D). 
To constitute the designed dRMCE system the genomic part of RMCE-2 was 
integrated into the murine ES cell line B6/RMCE, already bearing the R26 RMCE 
system, to yield a cell line comprising two loci prepared for RMCE. The locus of 
collagen, type I, alpha 1 (Col1a1) was chosen for integration of RMCE-2 as a promising 
candidate. This locus was previously targeted by Beard et al.. Transgenes inserted at the 
Col1a1 locus exhibited high transcriptional active in almost every tissue (180, 181).  
The exact site of integration was located in an intergenic region about 0.5 kb downstream 
of the 3´UTR of the Col1a1 gene and about 7 kb upstream of the Sarcoglycan α gene. A 
targeting vector, pCol1a1T(RMCE_2Neo), was cloned for integration of the genomic part 
of the RMCE-2 system via homologous recombination (Fig. 8A). Beside the described 
elements of the RMCE-2 system pCol1a1T(RMCE_2Neo) carries a loxP flanked, PGK 
driven, Neo resistance gene to afford antibiotic selection after targeting. The targeted 
Col1a1(RMCE-2Neo) allele was confirmed by Southern blot (Fig. 8C). Signals were 
expected for Col1a1 wt allele and Col1a1(RMCE-2Neo) at 9.3 kb and 8.5 kb, 
respectively. Neo was subsequently removed by Cre-deletion after successful targeting, 
to make G418 available for selection after exchange in R26(RMCE) again. The resulting 
Col1a1(RMCE-2) locus was detected by Southern blot (Fig. 8D). Expected sizes for 
Col1a1 wt allele, Col1a1(RMCE-2Neo) and Col1a1(RMCE-2) were 8.3 kb, 10.4 kb and 
9.5 kb, respectively. By insertion of RMCE-2 in Col1a1 of B6/RMCE the ES cell line 
B6/dRMCE was generated, carrying two independent RMCE alleles in R26(RMCE) and 
Col1a1(RMCE-2). 
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Fig. 8: Generation of ES cell line B6/dRMCE. A)The genomic part of RMCE-2 was integrated into the 
Col1a1 locus of B6/RMCE ES cells using the targeting vector pCol1a1T(RMCE_2Neo). A loxP flanked 
Neo resistance gene was used for selection after targeting. B) The site of integration is situated about 500 
bp downstream of the 3´UTR of the Col1a1 gene. C) Targeted Col1a1(RMCE-2Neo) allele was detected by 
Southern Blot. Expected sizes for Col1a1 wt allele and Col1a1(RMCE-2Neo) were 9.3 kb and 8.5 kb, 
respectively. Neo was deleted by Cre after targeting. E) The resulting Col1a1(RMCE-2) locus was detected 
3 Results 
                                                               
 
-58- 
 
by Southern blot. Expected sizes for Col1a1 wt allele, Col1a1(RMCE-2Neo) and Col1a1(RMCE-2) were 
8.3 kb, 10.4 kb and 9.5 kb, respectively. 
 
 
Exchange Vectors for both systems were cloned to perform simultaneous 
integration in R26(RMCE) and Col1a1(RMCE). Both vectors were designed as shRNA 
expression vectors. The vector pC-shIR5 was cloned as an exchange in Col1a1(RMCE-2) 
and for expression of shIGF1R2. For integration in R26(RMCE) and expression of 
shIGF1R2 the vector  pR-shIGF1R2 was constructed. Transfection of both vectors in 
B6/dRMCE was performed concurrently to achieve integration of both shRNA 
expression cassettes. To elucidate whether exchange is specific for each RMCE-system 
cells were separately transfected with each singular exchange vectors. Selection was 
carried out with puromycin and, or G418, according to transfected exchange vectors.  
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Fig. 9: Integration of inducible shIR5 and shIGF1R2 expression vectors applying dRMCE in 
B6/dRMCE cells. A) Col1a1 RMCE exchange vector pC-shIR5 and R26 RMCE exchange vector pR-
shIGF1R2 for inducible RNAi were simultaneously transfected into B6/dRMCE do be integrated via 
dRMCE. B) Clones positive for Col1a1(shIR5) and R26(shIGF1R2) were selected using puromycin and 
G418 in respect to the selection markers of both RMCE-systems.  C) Expression of shIR5 and shIGF1R2 
by the H1tetO promoter can be induced by administration of doxycycline (dox). 
 
 
Correct integration of each donor cassette into it´s dedicated RMCE loci was 
confirmed by Southern blot (Fig. 10). Two external probes were used for validation of 
each RMCE locus. Col5´and Col3´ probes were applied for validation of exchange in 
Col1a1(RMCE) and Rosa5´and Rosa3´ probes for exchange in R26(RMCE). Furthermore 
the internal probes iNeo and iPuro were used. Used restriction enzymes (RE) and 
expected fragment sizes for wild type (wt) alleles of R26 and Col1a1 as well as for 
RMCE alleles, R26(RMCE) and Col1a1(RMCE-2), before and after exchange given by 
each probe are listened in table 12. 
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allele 
 
probe: RE                 
R26 
(wt) 
Col1a1 
(wt) 
R26 
(RMCE) 
Col1a1 
(RMCE-2) 
R26 
(shIGF1R2) 
Col1a1 
(shIR5) 
Rosa5´: HindIII 4.4 kb - 3.9 kb - 6.2 kb - 
Rosa3´: BamHI 5.8 kb - 9.5 kb - 3.2 kb - 
Col5´: MfeI - 10.7 kb - 4.2 kb - 5.0 kb 
Col3´: AvrII/BmtI - 8.3 kb - 11.6 kb - 6.0 kb 
iPuro: EcoNI - - 8.9 kb 14.6 kb 6.7 kb 7.0 kb 
iNeo: BamHI - - - - 5.5 kb - 
 
Table 12: Expected fragment sizes in Southern blot analysis of dRMCE. Used restriction enzymes (RE) 
an expected fragment sizes resulting from each relevant allele are shown for corresponding probe.  Wild 
type alleles, Col1a1(wt) and R26(wt), RMCE alleles before exchange R26(RMCE) and Col1a1(RMCE-2), 
as well as RMCE alleles after exchange Col1a1(shIR5) and R26(shIGF1R2) are listened. 
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Fig. 10: Southern Blot analysis after  dRMCE in B6/dRMCE. Correct exchange in R26(RMCE) and 
Col1a1(RMCE-2) is shown by using internal and external binding probes: A) Col5´, B) Col3´, C) Rosa5´, 
D) Rosa3´, E) iNeo and F) iPuro. Expected signals sizes for wt alleles and RMCE alleles before and after 
exchange are listened in table 12. Transfected exchange vectors are indicated above. pC-shIR5 and   
pR-shIGF1R2 were transfected together to achieve dRMCE, whilst both vectors were transfected solely for 
single integration into their distinct loci. Untransfected B6/RMCE and B6/dRMCE cells were used as 
control. 
 
 
Among the 7 depicted clones, transfected with both exchange vectors, 5 displayed 
the expected pattern of both RMCE cassettes exchanged, showing signals of 
Col1a1(shIR5) and R26(shIGF1R2) as well as wt alleles of R26 and Col1a1.  
All clones transfected with single R26 exchange vector, pR-shIGF1R2, had the expected 
signals of the exchanged R26(shIGF1R2) allele, not exchanged Col1a1(RMCE) allele 
and both wt alleles. Among clones transfected with single Col1a1 exchange vector, pC-
shIR5, just clone #1 displayed signals of the exchanged RMCE-allele Col1a1(shIR5), 
unexchanged R26(RMCE) and both wt alleles.  
 Altogether 45 puromycin and G418 resistant clones yielded after divers 
accomplished transfections with both exchange vectors were analysed by Southern blot 
(data not shown). 36 of these had the expected pattern of both RMCE loci exchanged, 
demonstrating that dRMCE was successful in about 80 % of cells resistant to both 
antibiotics. 6 clones received from transfection solely with R26 exchange vector were 
verified (data not shown). Four of these were positive for single exchange in R26 in 
Southern blot. Negative clones gave wrong signals for R26 probes but not for the other 
applied probes, suggesting that recombinase mediated interactions of the R26 exchange 
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vector are restricted to its dedicated RMCE locus. Moreover, 10 clones obtained after 
transfection exclusively with the Col1a1 exchange vector were analysed (data not 
shown). Six of these were positive with all the probes. Two of the negative clones 
showed divergent signals for R26 probes, suggesting undesired interactions of the Col1a1 
exchange vector with the R26 RMCE locus. 
 For further demonstration of RMCE integration the KDs, triggered by the inserted 
shRNAs cassettes were verified by qPCR analysis. Silencing of both target genes was 
verified in clones, harbouring either a single or both shRNA expression cassettes, after 
inducing RNAi by dox treatment (Fig. 11). Target gene expression in untreated (-dox) 
cells of each clone was set as 100 %. Doxycycline induced and uninduced B6/dRMCE 
cells served as control.  
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Fig. 11: KD in ES cells obtained from single and double RMCE in B6/dRMCE. Expression of A) IR 
and B) IGF1R was measured in clones bearing either Col1a1(shIR5) or R26(shIGF1R2) after single RMCE 
and in clones bearing both loci exchanged after dRMCE. Target gene expression was determined after 
inducing RNAi by dox administration (+dox, white bars). Accordant gene expression in untreated cells (-
dox, grey bars) of each clone was set as 100%. Untransfected B6/dRMCE cells (black bars) served as 
negative control under induced and not induced conditions. Detection of target genes was performed in 
duplicate of each clone and are shown in percent of expression in  induced B6/dRMCE cells (+dox, black 
bars). Values are mean ± SEM.  
 
 
In accordance to the integrated shRNAs, clones bearing both exchanged RMCE 
loci, Col1a1(shIR5) and R26(shIGF1R2), displayed silencing of either target genes. IR 
expression was reduced to about 10 % and IGF1R expression to about 15 % of the 
original mRNA levels. Single transfected clones just exhibited target mRNA reduction 
accordant to the integrated shRNA expression unit. IR expressions were reduced to about 
20 % in single transfected cells bearing Col1a1(shIR5), whilst IGF1R mRNA levels were 
unaffected. The opposite picture was observed in cells bearing R26(shIGF1R2). IGF1R 
mRNA levels were reduced to about 30 % whilst IR expression remained unchanged.  
 Taken together, a murine ES cell line was generated bearing two independent 
RMCE alleles, R26(RMCE) and Col1a1(RMCE). Functionality of dRMCE was 
demonstrated by simultaneous integration of two shRNA expression cassettes. Specific 
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exchange in both loci was confirmed by Southern blot and indirectly confirmed by KD of 
both target genes, demonstrated functionality of dRMCE in the given cell line. dRMCE 
showed to work with an efficiency of about 80%.  
 
 
3.1.3 Evaluation of Col1a1 as a locus for transgenic expression (first strategy) 
In parallel to the generation of B6/dRMCE Col1a1 was characterized avoiding the 
complexity of constituting the RMCE-2 allele to clarify whether the locus fulfills the 
central demands for RMCE applications in terms of transgene expression properties for 
shRNAs and mRNAs. An inducible shRNA expression construct (VaLo_shEgln1) was 
designed to be inserted at the positions intended for RMCE-2 integration (Fig. 12A). 
VaLo_shEgln1 bears the elements of the doxycycline inducible shRNA expression 
system: H1tetO promoter, shRNA and CAGGS promoter driven tetR gene and a PGK 
driven Neo gene for selection after targeting. Due to interest of an independent project, an 
shRNA against EGL nine homolog 1 (Egln1) was used for locus validation.  Integration 
of VaLo_shEgln1 allowed evaluating the efficiency and functionality of the inducible 
shRNA expression system as well as the expression profile of transgenic mRNAs 
integrated in Col1a1. Col1a1(VaLo_shEgln1) positive clones were identified by Southern 
blot after targeting (Fig. 12B). Expected sizes for Col1a1 wt allele and 
Col1a1(VaLo_shEgln1) were 9.5 kb and 7.9 kb, respectively. 
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Fig. 12: VaLo_shEgln1 was used for characterization of Col1a1 as a locus for RMCE-2 application.  
VaLo_shEgln1 affords evaluation of Col1a1 as a locus for the application of the inducible RNAi system as 
well as for expression of transgenic mRNAs. A) The components of VaLo_shEgln1 were Neo driven by 
PGK promoter, pA, H1tetO promoter, shEgln1, and CAGGS driven tetR gene. VaLo_shEgln1 was 
integrated at the position designated for integration of RMCE-2 system downstream of Col1a1. B) Correct 
integration was verified by Southern blot. Expected sizes for Col1a1 wt allele and ol1a1(VaLo_shEgln1) 
were 9.5 kb and 7.9 kb, respectively. C) RNAi was induced in three ES cells bearing 
Col1a1(VaLo_shEgln1) (+dox, white bars) and compared to cells under not induced conditions (-dox, gray 
bars). Untreated (-dox, grey striped bar) and induced (+dox, white striped bars). R26(Egln1) cells served as 
a reference for KD efficiency. Not induced (-dox, dark grey) and induced wild type cells (+dox, black bars) 
served as negative control. Egln1 mRNA levels were detected in duplicated for each clone and are shown 
as percent of expression in induced wild type cells. Values are mean ± SEM.  
 
 
First indications about the characteristics of Col1a1 were obtained from analyzing 
the shRNA mediated silencing of Egln1 in ES cells (Fig. 12C). Target mRNA reduction 
was measured under doxycyclin induced and not induced conditions in three clones 
bearing Col1a1(VaLo_shEgln1). Induced and not induced B6/RMCE cells served as 
negative control. Egln1 mRNA levels were reduced to about 5 % of their original 
concentration upon induction. R26(shEgln1) cells, expressing shEgln1 employing the 
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same inducible system, served as a reference for RNAi efficiency and displayed target 
gene reduction comparable to Col1a1(shEgln1) cells. 
After obtaining promising results in ES cells heterozygote 
Col1a1(VaLo_shEgln1) mice were generated to examine RNAi efficiency and transgene 
expression from Col1a1 in vivo. Silencing of Egln1 was determined in male mice after 
inducing RNAi for 10 days by feeding chow containing 1g doxycyclin /kg. Not induced 
target mice as well as induced and not induced wt mice served as control. Remaining 
Egln1 levels were measured in total brain, heart, skeletal muscle, liver, kidney, spleen, 
epigonadal white adipose tissue (EWAT) and brown adipose tissue (BAT) by pPCR (Fig. 
13A). R26(shEgln1) mice served as a reference for KD efficiency and functionality of the 
inducible system (Fig. 13B). Expression rates in induced wt mice were set as 100 % for 
each tissue. Egln1 expression in induced Col1a1(VaLo_shEgln1) +dox mice was reduced 
to levels ranging between 2 % remaining mRNA in heart, skeletal muscle and kidney as 
best results and about 16 % in spleen. Despite in liver and spleen observed RNAi 
efficiencies were comparable or even slightly higher compared to mRNA reduction 
observed in R26(shEgln1), resulting in a remaining Egln1 expression between 3% and 
10%. Unfortunately untreated Col1a1(VaLo_shEgln1) -dox control mice exhibited 
significant reduction of Egln1 mRNA in several tissues without shRNA expression being 
induced by doxycyclin administration, reflecting an insufficient control of shRNA 
expression by the given RNAi system in Col1a1. Leakiness occurred strongest in kidney 
showing a KD to 13 %. Brain, heart, liver, spleen, EWAT and BAT display reductions of 
target gene transcription to between 30 % and 60 % in control target animals. Among the 
examined tissues tightly controlled RNAi was only observed in muscle. Tissue depended 
leakiness is a known disadvantage of the employed RNAi system. Integrated in R26 this 
effect commonly occurs in brain and kidney as confirmed by the shown data (Fig. 13B). 
Slight target mRNA reduction was observed for BAT of control animals, as well. In 
contrast to Col1a1(VaLo_shEgln1) samples, the remaining tissues, considered for R26, 
exhibited tight controlled RNAi. 
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Fig. 13: Inducible RNAi in Col1a1(VaLo_shEgln1) mice. KD efficiency and inducibility of 
Col1a1(VaLo_shEgln1) were evaluated in brain, heart, skeletal muscle, liver, kidney spleen, epigonadal 
white adipose tissue (EWAT), brown adipose tissue (BAT). A) Egln1 expression is shown in untreated (-
dox, light grey bars) and dox induced (+dox, white bars) Col1a1(VaLo_shEgln1) mice. Not induced (-dox, 
dark grey) and induced wild type mice (+dox, black bars) served as negative control. B) R26(shEgln1) 
mice, encoding shEgln1 in a VaLo_shEgln1 accordant construct integrated in R26, served as a reference for 
efficiency. Egln1 expression was detected in untreated R26(shEgln1) mice (-dox, light grey striped bars) 
and mice upon doxycyclin induction (+dox, white striped bars). Not induced (-dox, dark grey) and induced 
wild type mice (+dox, black bars) were used as negative control. Remaining Egln1 mRNA levels were 
estimated by qPCR and displayed as percentage of expression in doxycycline treated wild type mice (+dox, 
black bars). All values are mean ± SEM. For each group n=3. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 
versus wt -dox. 
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Lastly, transgenic mRNA expression properties of Cola1a were verified by 
determining the transcription pattern of CAGGS driven tetR gene in 
Col1a1(ValLo_shEgln1) mice. Egln1 mRNA was detected in brain, skeletal muscle, 
liver, spleen, kidney and EWAT and BAT and was compared to the expression pattern 
given by R26 integrated teR gene transcribed by the same promoter (Fig.14). Results 
were adjusted by forming delta-Ct (dCt) obtained after subtraction of the cycle threshold 
(Ct) for the housekeeping gene heterochromatin protein 1 binding protein 3 (HP1BP3) 
from the CT of tetR mRNA. Col1a1(VaLo_shEgln1) mice exhibited significant lower 
tetR expression rates in brain, skeletal muscle, liver, kidney and EWAT, compared to 
R26 expressed tetR. dCT differed between 15 CTs in muscle and 7 CTs in kidney, 
approximately corresponding an 3,200 to 130 fold lower expression of Col1a1 encoded 
tetR gene, compared to R26 inserted gene. In contrast tetR expression from 
Col1a1(VaLo_shEgln1) was higher in BAT by 3 CTs and heart by 2 CTs, approximating 
an 4 to 250 times higher expression rate in these tissues, compared to R26 integrated 
tetR. Both loci revealed comparable tetR expression levels in spleen.    
 
 
 
Fig. 14: Transgic mRNA expression in Col1a1(VaLo_shEgln1) mice. Expression of tetR was 
determined in brain, heart, skeletal muscle, liver, kidney spleen, epigonadal white adipose tissue (EWAT), 
brown adipose tissue (BAT) of  Col1a1(VaLo_shEgln1) mice using qPCR. Expression rates of Col1a1 
encoded tetR-gene (white bars) were compared to expression of tetR in R26(shEgln1) mice  (white striped 
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bars), encoding tetR in a VaLo_shEgln1 accordant construct integrated in R26. Results were normalized by 
calculating dCT (CT tetR - CT HP1BP3). All values are mean ± SEM. For each group n=3. 
 
 
In conclusion, VaLo_shEgln1 was employed to characterize Col1a1 as a locus for 
RMCE applications. Efficient RNAi was triggered by shRNAs expressed from 
Col1a1(VaLo_shEgln1). Indeed, the employed inducible RNAi system turned out to be 
not tightly controllable in Col1a1. Almost all examined tissues exhibited severe target 
gene reduction without shRNA expression being induced by dox administration. 
Furthermore expression pattern of tetR was analysed, as an example for transgene 
mRNAs integrated in Col1a1. Col1a1(VaLo_shEgln1) gave a considerable lower tetR 
expression in most considered tissues, compared to R26 integrated tetR. With regard to 
these results, Col1a1 was not considered as a locus for the integration of the genomic 
RMCE-2 part and the strategy of using two independent shRNA expression loci was not 
further evaluated. 
 
 
3.1.4 Stable single copy integration of two shRNA expression units in R26  
(second strategy) 
The second strategy to obtain silencing of two target genes was the integration of 
two shRNA expression units combined in a single R26 RMCE exchange cassette. To 
determine whether the order of shRNA cassettes affects the activity of the promoters, two 
constructs were designed bearing the same shRNA units but in reverse successions (Fig. 
15A). Tandem constructs were designed for the simultaneous expression of shIR5 and 
shIGF1R2. The vector pshIR5_shIGF1R2 carries H1tetO_shIR5 at the 5´ position and 
H1tetO_shIGF1R at the 3´position. In contrast, H1tetO_shIGF1R was followed by 
H1tetO_shIR5 in pshIGF1R2_shIR5. Both vectors were stably integrated via RMCE into 
R26 locus of B6/RMCE cells. Correct integration was controlled by Southern blot (Fig. 
15B). Expected signal sizes were 4.3 kb for R26 wt allele, 3.8 kb for R26(RMCE) allele 
before exchange and 6.2 kb for R26(RMCE) allele after exchange. 
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Fig. 15: Tandem shRNA expression constructs and achieved KD of target genes in ES cells. A) Two 
R26 exchange vectors comprising two H1tetO_shRNA units were design to achieve simultaneous silencing 
of IR and IGF1R A). pshIR5_shIGF1R and pshIGF1R_shIR5 bear two independent  shRNA expression 
units in reverse orders. Integration of exchange vectors was confirmed by Southern blot analysis. B) 
Expected sizes for R26  wt allele, R26(RMCE) allele before exchange and after exchanged were 4.3 kb, 3.8 
kb and 6.2 kb, respectively. KD of IGF1R C) and of IR D) was estimated by qPCR in  not induced (-dox, 
white bars) and induced (+dox, light grey bars) cells in duplicates of two clones per construct. Target gene 
reduction triggered by tandem constructs was compared to solely expressed shRNAs. Induced (+dox, dark 
gey bars) and not induced (-dox, black bars) B6/RMCE cells served as negative control. Remaining 
expression of target genes after induction is shown as percentage of not induced (-dox, light gey bars) cells 
of each accordant clones. All data are presented as mean ± SEM. 
 
 
KD of both target genes was measured and compared to the efficiency given by 
solely expressed shRNA (Fig. 15C, D).  Both tandem constructs reduced target gene 
expression at comparable magnitude. Remaining expression rates of IFG1R mRNA in 
R26(shIR5_shIGF1R2) and R26(shIGF1R2_shIR5) bearing clones were ranging between 
12 % and 20 %. Concurrently IR mRNA levels were reduced to between 18 % and 28 % 
of the original concentration. Compared to the solely expressed shRNAs either double 
constructs triggered a distinct lowered but still strong reduction of both target mRNAs. 
IGF1 expression was reduced to 12% in R26(shIGF1R2) cells and IR expression to about 
16 % in R26(shIR5) cells. To translate these results into an in vivo setting transgenic mice 
were generated from R26(shIGF1R2_shIR5) ES cells. RNAi was induced in 6 week old 
male mice by feeding chow containing 1g doxycyclin /kg. Tissue samples of pituitary, 
hypothalamus, total brain, heart, skeletal muscle, liver, kidney, spleen, pancreas, EWAT 
and BAT were dissected after 10 days of induction to estimate expression rates of IR and 
IGF1R by qPCR (Fig. 16).  
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Fig. 16: KD of IR and IGF1R mediated by shIGF1R2_shIR5 in vivo. Silencing of IR A) and IGF1R B) 
was estimated in selected tissues collected from doxycyclin induced (shIGF1R_IR5 +dox, light grey bars) 
and not induced (shIGF1R_IR5 -dox, white bars) male target mice by qPCR. Induced (wt +dox, dark grey 
bars) and not induced (wt -dox, black bars) wilfd type males served as negative control. Remaining 
expression of target genes is displayed as percentage of not induced  wt mice. For all groups n= 3, data are 
mean ± SEM. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 versus control. 
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A significant reduction of both target genes upon doxycyclin treatment was 
observed in all tissues examined from shIGF1R2_shIR5+dox mice. IR mRNA levels 
were reduced to about 10% remaining in pituitary, heart, skeletal muscle and EWAT, as 
strongest effects. Other tissues exhibited a reduction to between 20 % in BAT and 50 % 
in spleen. IGF1R expression was reduced to between 10 % and 30 % in the analysed 
tissues. Notably silencing of both target genes was considerably low in liver, otherwise 
providing high KD efficiencies. Results of measurements on EWAT samples displayed a 
high level of variation. Subsequently performed qPCR on EWAT samples of 
shIGF1R2_shIR5 +dox mice revealed a reduction of IGF1R expression to 40 % (Fig. 
17A). However, accomplished reduction of both target genes was seen as sufficient to 
examine the coherency of IR and IGF1R function in terms of glucose metabolism.  
 
 
3.2 Phenotypical analysis of insulin- and IGF1-receptor double 
knockdown mice 
 
3.2.1 Confirmation of IR and IGF1R knockdown 
The generated shIGF1R2_shIR5 mouse line enables the temporally inducible 
RNAi- mediated ablation of the insulin and the IGF1 receptor. This model offers a unique 
opportunity to study the potentially redundant roles of IR and IGF1R action in terms of 
energy homeostasis in adult mice, bypassing developmental defects arising from receptor 
ablation during embryonic development. To complete the experimental arrangement 
shIGF1R2 and shIR5 single KD mice were generated, serving as control groups in the 
following studies. Expression of shRNAs was induced in 6 week old male mice by 
administration of a doxycycline-containing diet, while control groups received normal 
chow. The following experiments were carried out within 4 weeks of induction, since 
ablation of both receptors was lethal after 4 weeks due to unspecified reasons. 
 
3 Results 
                                                               
 
-74- 
 
Silencing of insulin and IGF1 receptors was analyzed after 4 weeks of dox 
treatment by qPCR (Fig. 17A-19A) and Western blot (Fig. 17B-19B) in pituitary, total 
brain, skeletal muscle, liver and brown adipose tissue (BAT). Due to the low expression 
levels of IGF1R in liver, KD was only demonstrated by qPCR and not confirmed by 
Western blot in this tissue (182, 183). Since shIGF1R_IR5 +dox and shIR5 +dox mice 
had completely lost their white fat after 4 weeks, epigonadal white adipose tissue 
(EWAT) samples were collected separately from 7 week old mice after 10 days of 
induction to demonstrate shRNA mediated gene silencing this tissue. 
Upon doxycycline induction of shRNA transcription, both single KD mice display 
specific silencing of the correspending target gene with no impact on the expression of 
the second gene. 
There was a similar decrease in IR expression of 15 % to 20% in the analyzed tissues of 
shIR5 +dox and shIGF1R2_shIR5 +dox mice. In contrast, double KD mice display a 
considerable lower silencing in IGF1R expression, 2-fold weaker in muscle, pancreas, 
EWAT and BAT, compared to shIGF1R single KD mice. This finding indicates a 
position effect within the tandem construct leading to lowered transcriptional activity of 
the H1tetO promoter at the first position. The circumstance that double KD mice display 
IGF1R silencing at a lower degree than the single KD control group must be considered 
in the interpretation of the following findings. 
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Fig. 17: KD of IR and IGF1R in shIGF1R2_shIR5 mice. Silencing of IR A) and IGF1R B) was 
estimated in selected tissues of dox induced (shIGF1R_IR5 +dox, light grey bars) and not induced 
(shIGF1R_IR5 -dox, white bars) male target mice by qPCR. Induced (wt +dox, dark grey bars) and not 
induced (wt -dox, black bars) wild type males served as negative control. Remaining expression of target 
genes is displayed s percentage of not induced wt mice. C) Western blot analysis of IR, IGF1R and Akt 
(loading control).  For all groups n= 3. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 versus wt -dox control. 
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Fig. 18: KD of IGF1R in shIGF1R2 mice. Expression levels of IR A) and IGF1R B) were estimated in 
selected tissues of  dox induced (shIGF1R_IR5 +dox, light grey bars) and not induced (shIGF1R_IR5 -dox, 
white bars) male target mice by qPCR. Induced (wt +dox, dark grey bars) and not induced (wt -dox, black 
bars) wild type males served as negative control. Remaining expression of target genes is displayed s 
percentage of not induced wt mice. C) Western blot analysis of IR, IGF1R and Akt (loading control).  For 
all groups n= 3. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 versus wt -dox control. 
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Fig. 19: KD of IR in shIR5 mice. Expression levels of IR A) and IGF1R B) were estimated in selected 
tissues of  dox induced (shIGF1R_IR5 +dox, light grey bars) and not induced (shIGF1R_IR5 -dox, white 
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bars) male target mice by qPCR. Induced (wt +dox, dark grey bars) and not induced (wt -dox, black bars) 
wild type males served as negative control. Remaining expression of target genes is displayed s percentage 
of not induced wt mice. C) Western blot analysis of IR, IGF1R and Akt (loading control).  For all groups 
n= 3. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 versus wt -dox control. 
 
 
3.2.2 Serum levels of Insulin and IGF1 in double knockdown mice 
The emergence of resistance to insulin and IGF1 in mice with silencing in both 
corresponding receptors was investigated by detection of circulation hormones, to 
demonstrate compensatory release (Fig. 20). Insulin levels were determined by Enzyme-
linked Immunosorbent Assay (ELISA) in samples collected daily in the first week of 
induction and in a weekly interval for the 3 consecutive weeks. Furthermore, serum 
levels of IGF1 were analyzed after 4 weeks of dox treatment. 
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Fig. 20: Compensatory changes in serum levels of insulin, not of IGF1. A) Concentrations of circulating 
insulin were monitored from beginning of doxycyclin induction over a period of 4 weeks in  shIGF1R_IR5 
+dox (filled diamond), shIR5 +dox (filled triangle), shIGF1R +dox (filled rectangle), wt +dox (filled circle) 
and wt -dox (open circle) mice.  Statistical significance was calculated using two-way ANOVA, followed 
by a Bonferroni post-test. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001. B) Separate depiction of serum insulin 
levels of serum insulin levels in shIGF1R2 +dox, shIR5 +dox and shIGF1R2_shIR5 +dox mice in relation 
to wt -dox (black bar) and wt +dox (dark grey bar) controls at the end of experiment (day 28). Statistical 
significance was calculated using two-tailed t-test versus wt -dox. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 
0.001. C) Serum concentrations of IGF1 were determined in dox treated (light grey bars) and untreated 
(white bars) mice of each group in week 4 after of dox induction. wt -dox (black bar) and wt +dox (dark 
grey bar) served as controls. For each group n= 5. All data are presented as mean ± SEM. Statistical 
significance was calculated using two-way ANOVA, followed by a Bonferroni post-test. *, P ≤ 0.05; **, P 
≤ 0.01; ***, P ≤ 0.001. For each group n= 5. All data are presented as mean ± SEM. 
 
 
Serum insulin concentrations rose drastically beginning from day 3 of induction 
in induced shIGF1R2_IR5 +dox and shIR5 +dox mice, reflecting a compensatory 
increase of insulin secretion due to target tissue resistance. Serum concentration of both 
groups peaked at 28 ng/ml at day 7. Values fluctuated between 23 ng/ml and 30 ng/ml in 
the following 3 weeks. No clear differences in the kinetics of onset or magnitude of 
compensatory increase in insulin concentrations were observed between shIGF1R2_IR5 
+dox and shIR5 +dox mice. A comparably subtle but significant, 3-fold, increase of 
serum insulin was observed in mice with silencing of the IGF1R, starting from week 2 of 
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induction. This elevation did not reach significance in ANOVA test performed on whole 
data representing temporal progress of insulin release (Fig. 20A). However, separate 
statistical analysis of insulin values at day 28 using two-tailed t-test revealed an increase, 
which was significant versus wt -dox controls (Fig. 20B). Control wt mice, induced and 
not induced, displayed no changes in insulin serum levels. 
Serum concentrations of IGF1 were analyzed in samples taken in week 4 of dox 
treatment (Fig. 20C). No significant differences between induced KD mice and wt control 
groups were observed, demonstrating the absence of compensatory increased release of 
IGF1 due to whole body ablation of the IGF1R.  
 
 
3.2.3 The effects of IR and IGF1R KD on energy homeostasis and somatic growth 
 Common physical parameters including body weight, fat content, body length and 
food intake were determined to investigate the effects of disturbed energy homeostasis 
and somatic growth. 
Body weight of induced mice and control groups was monitored weekly from 
beginning of dox administration in the age of 6 weeks. The weight curve of induced mice 
is depicted in Fig. 21A. Not induced control groups as well as induced wt +dox mice are 
shown in Fig. 21B. Induced double KD mice (shIGF1R2_shIR5 +dox) continuously lost 
weight to a mean value of 11 g after 4 weeks. Moreover, also shIR5 +dox mice 
considerably lost body mass, however not to the same extent as double KD mice. Induced 
shIGF1R2 +dox mice however showed no alteration in body weight after start of 
induction. Here, body weight did not increase over 19 g, indicating an arrest of somatic 
growth due to ablation of the IGF1R. Among the control groups, induced and not induced 
wt mice, wt +dox and wt -dox, and shIR5 -dox mice continuously gained weight to a 
final body weight of about 22 g. Notably, not induced shIGF1R2_shIR5 -dox and 
shIGF1R2 - dox mice display lower body weight at any time, compared to wt mice and 
shIR5 -dox mice.  
To further assess the effects of insulin and IGF1 receptor ablation on lipid 
metabolism, body fat content was dermined in week 5 of induction using nuclear 
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magnetic resonance (NMR). Fat content is displayed as percentage of whole body weight 
(Fig. 21C). Induced shIGF1R2_shIR5 +dox and shIR5 +dox mice exhibited a significant 
decrease in body fat percentage to about 5 %. In contrast, body fat in animals with 
silencing in IGF1R was significantly increased to about 18 % of whole body mass. Not 
induced shIGF1R2 -dox mice showed a slightly increased fat content, not reaching 
significance. Wild type mice and not induced control groups displayed fat percentage of 
about 10 %. 
Since IGF1 action is a well-established anabolic signal, the effect of IGF1R 
silencing on somatic growth was verified by determination of body length after 4 weeks 
of doxycyclin treatment (Fig. 21C). Mean body length of shIGF1R2_IR5 +dox and 
shIGF1R2 +dox mice was significantly reduced to 85 and 86 mm. These data indicate 
that the cause for the observed reduction in body weight of IGF1R deficient mice is 
attributable to reduced somatic growth. Body length between control groups as well as 
induced shIR5 +dox mice was undistinguishable with about 90 mm. 
Furthermore, average food intake was determined daily in 11-week-old mice after 
4 weeks of induction (Fig. 21D). Food intake of shIGF1R2_IR5 +dox and shIGF1R2 
+dox mice was drastically reduced to about 3.2 g per day. Not induced control groups as 
well as doxycyclin induced wt +dox and shIR5 +dox mice showed no alteration. Daily 
average food intake of these groups was about 4.1 g per day.   
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Fig. 21: Body weight, fat content, length and food intake. A) Body weight was monitored in a weekly 
interval from beginning of induction of induced wild type wt +dox (filled circle), shIGF1R +dox (filled 
rectangle), shIR5 +dox (filled triangle) and shIGF1R_IR5 +dox (filled diamond). B) wt +dox (filled circle) 
and not induced control groups wt -dox (open circle), shIGF1R -dox (open rectangle), shIR5 -dox (open 
triangle) and shIGF1R_IR5 -dox (open diamond) are depicted separately. For all groups n =10. C) Body fat 
content was detected in week 5 of induction in 11 week old induced (light gray bars) and not induced white 
bars) mice. For all groups n =10. D) Body length was determined in week 5 of induction in 11 week old 
induced (light gray bars) and not induced (white bars) mice. For all groups n =10. E) Average daily food 
intake of dox treated (light gray bars) and untreated (white bars) mice was measured in week 4. For all 
groups n =5. Wt -dox (black bars) and wt +dox mice served as controls in determination of body fat 
content, body length, and food consumption. All data are presented as mean ± SEM. The statistical 
significance was calculated using two-way ANOVA, followed by a Bonferroni post-test. *, P ≤ 0.05; **, P 
≤ 0.01; ***, P ≤ 0.001; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001. 
 
 
Taken together, shIGF1R2_shIR5 +dox mice exhibited a multitude of physical 
changes, primarily reflected by a drastical reduction in body weight. This observation 
goes along with effects that were observed in single and double KD mice. Loss of IR 
function results in a severely decreased body fat content. Ablation of the IGF1R reduced 
somatic growth, demonstrated by arrested weight gain and reduced body length. 
Furthermore, IGF1R deficient mice display reduced food intake. 
 
 
3.2.4 The effect of IR and IGF1R silencing on glucose metabolism  
 To assess the impact of simultaneous KD of insulin- and IGF1-receptor on 
glucose metabolism, serum glucose concentrations were monitored for the duration of the 
experiment. The progression of blood glucose concentrations in dox induced mice of all 
groups is shown in Fig. 22A. Not induced control groups as well as induced wt mice are 
displayed separately in Fig. 22B. 
Blood glucose concentrations started to rise in shIGF1R2_IR5 +dox and shIR5 
+dox mice beginning from day 4 of induction, indicating the development of insulin 
resistance in target tissues. Notably, induced double KD mice, namely 
shIGF1R2_shIR5+dox, exhibited a distinctly faster increase of glucose levels during day 
5 and 6 after induction, compared to shIR5 +dox mice. However, both lines reached 
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values of 450 mg/dl glucose at day 7 and fluctuated between 380 mg/dl and 550 mg/dl 
until the end of the analysis period. In contrast, induced shIGF1R +dox mice revealed no 
elevation but rather slightly lowered blood glucose values compared to wt control groups. 
This decrease did not reach significance in ANOVA test performed on whole data 
representing temporal progress of glucose levels in all groups (Fig. 22A). However, 
separate statistical analysis of glucose values in shIGF1R +dox mice at day 28 using two-
tailed t-test revealed a decline, significant versus wt -dox controls at that point in time 
(Fig. 22B). Dox treated wt mice and not induced control groups showed no alterations 
over the time monitored. 
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Fig. 22: Blood glucose levels in shIGF1R_IR5 mice. A) Blood glucose concentrations in male wild type 
wt +dox (filled circle), shIGF1R +dox (filled rectangle), shIR5 +dox (filled triangle) and shIGF1R_IR5 
+dox (filled diamond) mice were detected  for a period of 4 weeks, daily in the first week of induction and 
in a weekly interval for 3 more weeks. B) Blood glucose values of wt +dox (filled circle) and not induced 
controls wt -dox (open circle), shIGF1R -dox (open rectangle), shIR5 -dox (open triangle) and 
shIGF1R_IR5 -dox (open diamond) are displayed separately. The statistical significance was calculated 
using two-way ANOVA, followed by a Bonferroni post-test. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001. C) 
C) Separate depiction of serum glucose levels of shIGF1R2 -dox (whithe bar) and shIGF1R2 +dox (light 
grey bar) mice in relation to wt -dox (black bar) and wt +dox (dark grey bar) controls at the end of 
experiment (day 28). Statistical significance was calculated using two-tailed t-test versus wt -dox. *, P ≤ 
0.05; **, P ≤ 0.01; ***, P ≤ 0.001. For each group n= 10. All data are presented as mean ± SEM. 
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To further elucidate to what extent double KD of IR and IGF1R affects insulin 
sensitivity of target tissues, insulin tolerance tests (ITT) and glucose tolerance tests 
(GTT) were performed. 
 ITT was performed in induced and not induced mice of all groups in week two 
after start of dox treatment (Fig. 23A, B). Induced shIR5 +dox and shIGF1R2_shIR5 
+dox mice showed no response, i.e. decrease in blood glucose, upon administration of 
exogenous insulin. Reduction of blood glucose concentrations was significantly lowered 
in induced shIGF1R2 +dox mice after insulin stimulation compared to wt +dox mice. 
Response to insulin in not induced control groups, shIR5 -dox, shIGF1R2 -dox, 
shIGF1R2_shIR5 -dox, wt -dox and induced wt was indistinguishable (Fig. 23B). 
In addition, GTT was performed in week 3 after beginning of induction (Fig. 23C, 
D). All KD mice exhibited reduced glucose clearance upon exogenous glucose 
administration (Fig. 23C). The highest degree of impairment was observed in 
shIGF1R2_shIR5 mice. Double KD of insulin and IGF1 receptor in shIGF1R2_IR5 +dox 
mice lead to a slightly higher rise in blood glucose concentrations upon exogenous 
administration, compared to shIR5 +dox mice. However, this difference did not reach 
statistical significance. Ablation of IGF1R in shIGF1R2 +dox mice significantly reduced 
peripheral glucose uptake, indeed at a less severe degree compared to shIR5 +dox mice. 
Glucose clearance was indistinguishable between not induced control groups (Fig. 23D). 
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Fig. 23: Insulin and glucose tolerance in double KD mice. ITT was performed in week 2 after induction. 
A) Blood glucose levels of induced wild type wt +dox (filled circle), shIGF1R +dox (filled rectangle), 
shIR5 +dox (filled triangle) and shIGF1R_IR5 +dox (filled diamond) were determined 15, 30 and 60 min 
after injection of insulin. B) ITT results of control groups, wt +dox (filled circle) and not induced controls 
wt -dox (open circle), shIGF1R -dox (open rectangle), shIR5 -dox (open triangle) and shIGF1R_IR5 -dox 
(open diamond), are displayed separately. GTT was accomplished in week 3 after start of doxycyclin 
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induction. C) Blood glucose concentrations of induced wild type wt +dox (filled circle), shIGF1R +dox 
(filled rectangle), shIR5 +dox (filled triangle) and shIGF1R_IR5 +dox (filled diamond) were detected 15, 
30, 60 and 120 min after injection of glucose. D) The GTT results of wt +dox (filled circle) and not induced 
wt -dox (open circle), shIGF1R -dox (open rectangle), shIR5 -dox (open triangle) and shIGF1R_IR5 -dox 
(open diamond) control groups are displayed separately. For each group n= 10. All data are presented as 
mean ± SEM. The statistical significance was calculated using two-way ANOVA, followed by a 
Bonferroni post-test. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001. 
 
In conclusion, mice with silencing in insulin and IGF1 receptor exhibited a 
stronger initial increase in serum glucose levels, compared to IR deficient mice, while the 
onset and magnitude of hyperglycemia were undistinguishable between both groups. 
Furthermore, double KD mice displayed a slightly reduced glucose clearance, compared 
to mice with silencing in IR, which however did not reach statistical significance. 
In contrast, no changes in blood glucose levels were observed in IGF1R deficient mice.  
Interestingly, these mice displayed severely impaired glucose tolerance and reduced 
insulin sensitivity.  
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4 Discussion 
 
4.1 Generation of murine ES cell line bearing two RMCE alleles (first 
strategy) 
The technical challenge of this thesis was the development of a system that allows 
the simultaneous shRNA-mediated knock down (KD) of two independent target genes in 
transgenic mice. The ablation of two target genes allows addressing a wider field of 
research issues by the RNAi technology, e.g. by silencing of redundant functions or 
compensatory pathways. Specifically, this study aimed to generate a tool to 
simultaneously and inducibly silence the insulin receptor and IGF1 receptor in a 
temporally controlled manner to analyze the role of IGF1R in compensating functions of 
IR in control of glucose metabolism and the development of type 2 diabetes mellitus 
(T2DM). Two distinct strategies were pursued to enable the integration of two shRNA 
expression cassettes, allowing the tet-repressor mediated temporal control of RNAi, to 
achieve the KD of two target genes.  
The first strategy based on the generation of a cell line harbouring two alleles 
prepared for cassette exchange, allowing the simultaneous integration of two independent 
shRNA expression cassettes at the two genomic loci. This dRMCE technology provides a 
platform for a wide range of applications. Beside the simultaneous expression of two 
shRNAs, spare combinations of shRNA and mRNA expression units can be integrated in 
a simple and fast way using dRMCE. The most significant advantage of dRMCE is given 
by the employment of two segregating RMCE alleles. Proper assembly of experiments 
comprising two modified factors require the analysis of single modified mice lines as 
control groups. The dRMCE approach enables to achieve all three mouse lines just by 
generation and breeding of dRMCE-mice, carrying each shRNA expression unit in 
independently inherited loci. Reducing pre-experimental work in transgenic mouse 
generation to one line makes complex experiments using double modified mice much 
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more work-, time- and especially cost-efficient. These benefits make dRMCE an 
interesting technique for several applications.  
An established RMCE system mediating integration in Rosa26 (125) served as a 
technical basis for the constitution of the dRMCE cell line. A second Flp-based RMCE-
system, designated as RMCE-2, was designed to act independently from the one in 
Rosa26 to allow simultaneous and specific exchange in both RMCE loci. The specificity 
of cassette exchange in both systems was given by the use of 3 pairs of heterospecific 
FRT versions (168). RMCE-2 employed couples of FRT and F5 sites whilst the R26 
RMCE system makes use of FRT and F3 pairs, limiting cassette exchange through double 
reciprocal recombination to each associated couple of acceptor and donor cassette. 
Moreover, the architecture of the marker systems afforded antibiotic selection after 
specific exchange in both RMCE loci. Reconstitution of a puromycin resistance gene in 
RMCE-2 depends on the correct recombination of the FRT site, whereas activation of a 
neomycin resistance gene depends on recombination of the F3 site in the R26 system. 
Since FRT and F3 sites were part of the reading frame of the accordant resistance genes 
activation of those is exclusively given by exchange of R26 RMCE donor and acceptor 
cassette and RMCE-2 donor and acceptor cassette. 
A second more critical task was the identification of a genomic locus for 
integration of the RMCE-2 acceptor cassette, providing ubiquitous and high expression of 
transgenic shRNAs and mRNAs as well as tight control of the employed inducible RNAi 
system. Further, structural demands had to be fulfilled by a candidate locus. Integration 
of the RMCE-2 cassette should be preferably neutral in sense of minimizing the risks of 
interference with endogenous functions to avoid a possible phenotype, e.g. through 
disruption of ORFs, promoter elements or regulatory elements, as well as trans effects of 
integrated transgenic promotors. For this reason a site of integration in an intergenic 
region downstream of a well defined 3´ UTR was favoured. Additionally, the 
chromosomal position of the site of integration has to ensure independent inheritance of 
RMCE-2 allele and R26(RMCE) allele. The locus of Cola1 was chosen for integration of 
the genomic part of RMCE-2 as a promising candidate. Col1a1 was previously 
characterized by Beard et al. (181) who demonstrated strong and ubiquitous expression 
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of integrated cDNAs, independent from the expression pattern of the Col1a1 gene. These 
preceded studies strongly suggested properties of the Col1a1 locus fulfilling the demands 
for dRMCE applications. Beard et al. (181) targeted an intergenic region about 0.5 kb 
downstream of the 3´UTR of the Col1a1 gene with the neighboring gene Sarcoglycan α 
(Sgca) in reverse orientation and in a distance of 7 kb. This positioning 3´of both ORFs, 
with no further known transcripts between, was seen as a good option for integration of 
the RMCE-2 acceptor cassette avoiding unwanted effects on endogenous gene activity. 
At last, Col1a1 is located on Chromosome 11, assuring independent inheritance from the 
R26 locus on Chromosome 6.  
The genomic part of RMCE-2 was integrated in Col1a1 of a ES cell line bearing 
R26(RMCE), yielding a cell line with two loci prepared for cassette exchange. 
Functionality of dRMCE was successfully demonstrated by the simultaneous and 
independent integration of two RMCE donor cassettes for shRNA expression in 
R26(RMCE) and Col1a1(RMCE-2). Specificity of the dRMCE reaction for both distinct 
loci was demonstrated by Southern blot analysis. 80 % of cells resistant to both 
antibiotics turned out to be positive for both exchanged alleles in Southern blot analysis. 
This rate of yield was arithmetically the optimum to be expected since R26(RMCE), as 
the basic system of dRMCE, provides about 90 % positive clones, when used in single 
RMCE (125). As a test for specificity of each exchange reaction in each independent 
system, cells bearing both RMCE alleles were transfected with single exchange vectors, 
either for integration in R26(RMCE) or Col1a1(RMCE-2). Several Cells transfected with 
Col1a1 exchange vector showed changed signal pattern of R26 specific probes, 
suggesting interactions between Col1a1 exchange vector and R26(RMCE) locus. 
Single site recombination of the FRT sites, used in both RMCE systems, might facilitate 
the integration of Col1a1 exchange vector in R26(RMCE). Such a recombination event 
separates the truncated Puro gene from the pA, intended to block transcription after 
incorrect integration, and allows it ´s expression through transcriptional activities at the 
site of integration. Certainly the number of analysed clones was much too small for a 
reasonable evaluation of these effects, but point at a possibly reduced specificity of 
RMCE reaction in presence of the second RMCE locus.  
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Anyhow, specific integrations obviously seem to superpose unspecific interactions events 
between both RMCE systems and avoid the outcome of false integrations, as 
demonstrated by the high succession rate of dRMCE.  
As a further demonstration of dRMCE integration target gene silencing, triggered 
by the both integrated shRNA expression cassettes was estimated in ES cells. Remaining 
levels of both target genes mRNAs were reduced to comparable levels by vectors 
integrated via dRMCE when compared to the same vector solely integrated. This result 
demonstrates the functionality of dRMCE integrated shRNA expression vectors and 
further demonstrates the specific integration of R26 and Col1a1 exchange vectors into the 
accordant RMCE locus, since KD of target genes occurs only in clones expected to 
express corresponding shRNA. 
In parallel to the generation of the dRMCE system a simple RNAi construct was 
integrated into the Col1a1 locus to analyse it´s transgenic expression properties, avoiding 
the complexity of constituting RMCE-2. The used construct allowed evaluating the 
functionality of the employed inducible RNAi system, the degree of shRNA triggered 
target gene silencing and expression of transgenic mRNA. Transgenic mice were 
generated after obtaining promising in vivo results, showing KD levels comparable to 
those yielded by R26. Remaining mRNA levels of the target gene as well expression 
levels of the tetR mRNA were determined in several tissues. Unfortunately expectations 
for Col1a1 were nut fulfilled. Expression levels of tetR mRNA showed to be considerable 
lower, 130 to 3,200 times, in most considered tissues, than those given by R26 integrated 
tetR genes. Indeed, silencing effects achieved by Col1a1 expressed shRNA in vivo were 
comparable or even slightly higher than those of the same shRNA expressed from R26, 
but regrettably, control mice showed significant reductions of target gene mRNA in 
several tissues without shRNA expression being induced by doxycycline treatment. 
Uninduced KD occurs strongest in kidney showing a KD to 13 % of remaining target 
gene expression. Brain, heart, liver, spleen, WAT and BAT are ranging between a 
reduction to about 60 % to 30 %. This unwanted KD results from a insufficient regulation 
of the H1tetO -tetR system leading to shRNA expression without induction. Among the 
analyzed tissues only muscle shows tight controlled shRNA expression, only after Dox 
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administration. This tissue depended leakiness is a known disadvantage of the used 
shRNA expression system. Integrated in R26(RMCE) this effect most commonly occurs 
in brain and kidney and at lower degree in other tissues.  
Most likely the high degree of leakiness can be attributed to the low tetR expression 
found in most tissues. Further factors might be tissue specific CpG methylation patterns 
or chromatin condensation status at the site of integration, impairing the binding of tetR 
or its ability to block Polymerase III depend transcription. Further investigation on 
methylation status, shRNA expression levels, use of insulator sequences, such as the 
chicken hypersensitive site-4 (cHS4) (202) etc. might help to understand and to avoid 
tissue depend leakiness of the H1tetO system. Anyhow, testing more loci for their 
expression properties seems to be a more promising option to obtain a dRMCE system 
deployable for all estimated areas of use. In general loci of strong and ubiquitous 
expressed house keeping genes are used for transgene expression issues. While 
interrupting endogenous gene functions were to be preserved in this work, several sites 
inside the ORFs of house keeping genes has been tested as versatile integration loci for 
expression of transgenic cDNAs or shRNAs. Disregarding the heterozygote interruption 
of endogenous gene function, testing these loci as sites for RMCE-2 seems to be a 
promising option. Examples are the hypoxanthine phosphoribosyltransferase 1 (Hprt1) 
loci, used for constitutive shRNA expression, or the beta actin locus, used for cDNA 
expression (155, 203, 204). 
During the accomplishment of this project Turan et al. (205) demonstrated the 
functionality of a dRMCE system following the same principle applied in this work. 
In contrast to the application presented in this thesis, genomic parts were not integrated at 
defined loci for transgenic gene expression. In conclusion, the functionality of the 
designed dRMCE was successfully demonstrated and reached the optimum integration 
rate to be expected. Albeit Col1a1 did not fully fit expectations and can not be used for 
inducible RNAi applications, the locus can be used for insertion of constitutivly active 
RNAi constructs, since achieved KD of Col1a1 expressed shRNA was high in all 
investigated tissues. Further mRNA expression in Col1a1 was lower, compared to R26, 
but might be sufficient for applications of transgenic mRNA expression. The constructed 
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RMCE-2 system can be used for further work on dRMCE technique, since the benefits of 
dRMCE, as described above, justify further investigation on dRMCE and especially 
screening of alternative loci as a site for the integration of the genomic part of RMCE-2.  
 
 
4.2 Stable single copy integration of two shRNA expression units in R26 
(second strategy) 
The second strategy to obtain silencing of two independent target genes based on 
the combination of two dox inducible shRNA expression units in a single exchange 
vector for the integration into the R26(RMCE) allele. The combination of multiple 
shRNA expression units in one vector has been demonstrated before (206-208), but so far 
the adaptability of RMCE technology and the suitability of R26 locus for single copy 
integrations of tandem constructs have not been demonstrated. The tandem approach was 
very straight forward, compared to the dRMCE approach, since it employs the 
established R26 system and requires no further genomic modification. In contrast to the 
described double RMCE system this approach requires the independent generation of 
single KD control lines necessary, extending pre-experimental costs. 
Two tandem constructs, harbouring the expression units for shRNAs directed 
against IR and IGF1R in contrariwise orders, were analysed for their silencing efficiency 
in ES cells. Both constructs displayed reduction of both target gene’s expression at a 
degree comparable to solely expressed shRNAs and revealed no position dependence in 
promoter activity in ES cells.  Heterozygote mice bearing a shIGF1R2_shIR5 tandem 
construct displayed silencing of both receptors. Both promotors of the tandem construct 
displayed the same tissue dependent leakiness of the inducible H1tetO -tetR system in 
total brain as single RNAi cassettes does. Although no effects of the promoter’s positions 
were observed in ES cells, measurements of target gene expression in mice revealed a 
lowered silencing efficiency of the shRNA encoded at the first position in most analysed 
tissues. Double KD mice displayed a twofold weaker silencing in IGFF1R expression in 
several tissues compared to shIGF1R single KD mice. IGF1R mRNA was reduced to just 
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about 40% in muscle, pancreas, EWAT and BAT of double KD mice. Weather the 
downstream neighbouring promotor negatively influenced transcriptional activity or both 
shRNA compete within the RNAi pathway was not further investigated in this thesis. 
However, the generated mice line provided silencing in IR and IGF1R, allowing 
to investigate the effects of concurrent diminished expression of both receptors. The 
circumstance that double KD mice displayed IGF1R silencing at a lower degree than the 
single KD control group must be considered in the interpretation of the following 
findings. 
 
 
4.3 Phenotypical analysis of insulin- and IGF1-receptor double 
knockdown mice 
The genetic techniques successfully developed in this thesis made it possible to 
generate a mouse model that allows the concurrent RNAi-mediated ablation of the insulin 
and the IGF1 receptor. Temporally controlled double KD provides an excellent option to 
investigate the impact of whole body loss-of-function of both receptors, since 
conventional homozygous knock outs of either of these receptors results in embryonic 
and perinatal lethality (87, 209).  
The insulin receptor (IR) plays a central role in nutrient metabolism by regulating 
glucose and lipid homeostasis and inhibition of its signalling cascade leads to the 
development T2DM (209 -213). Inactivation of IR function in mice provides a basic 
diabetic model of insulin resistance through disruption of intracellular downstream 
signalling (for review see (214). The IGF1 receptor (IGF1R) is structurally closely 
related to the IR (33, 58, 60) The high degree of Homology facilitates low affinity 
binding of IGF1 and insulin to the IR and IGF1R, respectively (74, 80, 100-102). 
Nevertheless, although both receptors share the same major intracellular signalling 
pathways (33, 58-60), the biological effects of IGF1 signalling differ considerably from 
those of insulin. To date, IGF1 is mostly seen as an anabolic hormone and as a potent 
inhibitor of apoptosis (62-64, 87, 100). However, experimental evidence derived from 
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clinical trials as well as in vitro and in vivo studies assign an important role to the IGF1 
system in maintaining glucose homeostasis and in the development of T2DM. Low levels 
of circulating IGF1 were observed in type 2 diabetic patients and clinical trails revealed 
insulin-like effects of administered exogenous IGF1, reducing serum glucose levels at a 
magnitude of 4-7% of the effect of insulin itself (66, 68, 111-114). In line with these 
observations, administration or overexpression of IGFBPs, thereby modulating IGF1´s 
bioavailability, were demonstrated to impair glucose homeostasis (110, 115-118). These 
described insulin like effects of IGF1 are mainly attributed to peripheral glucose uptake 
in skeletal muscle, while the role of hepatocytes and adipocytes in this context is 
controversially discussed (70, 111, 120-124). Furthermore, IGF1 signalling has shown to 
influence insulin action itself, since function of the IGF1R turned out to be crucial for 
adequate glucose induced insulin release by the pancreatic β-cells (215 -217). 
The simultaneous ablation of IR and IGF1R allows to examine whether both 
receptors display redundant functions in regard to glucose and energy homeostasis and to 
assess the role of the IGF1 receptor in the emergence of T2DM. Accordingly, the 
generated double KD line was analyzed in terms of metabolic parameters. As a central 
focus of interest, the development of insulin resistance in shIGF1R2_shIR5 mice was 
investigated by monitoring serum levels of insulin and glucose. Performance of insulin 
tolerance tests (ITT) and glucose tolerance tests (GTT) afforded to further elucidate in 
which magnitude double KD of IR and IGF1R effects insulin sensitivity of target tissues. 
The impact of receptor ablation on overall energy homeostasis and somatic growth was 
assessed by monitoring physical parameters, including body weight, body fat content, 
body length and food consumption. 
 Mice that lack the insulin receptor exhibited a pronounced diabetic phenotype, 
reflected by elevated blood glucose levels, compensatory insulin release as well as severe 
impaired glucose tolerance and insulin sensitivity. Moreover, reduced body fat content 
and the complete lack of epigonadal white fat pads, indicated reduced uptake of 
circulating lipids and increased hydrolysis of triglycerides due to abrogated insulin 
action. However, further analyses have to be performed to characterize the changes in 
energy metabolism e.g. by analysis of serum lipid species and the expression of genes 
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involved in lipid and glucose metabolism. Disturbed energy homeostasis was also 
reflected by a severe loss of whole body weight. These findings of IR KD mice are in line 
with the results of previous studies employing shIR5 mice (218). 
Parameters of insulin and glucose metabolism display a mixed picture in the 
second control group with KD of the IGF1R. These animals displayed severe resistance 
to exogenous glucose, with only a minor reduction in insulin sensitivity, a slight increase 
in basal serum insulin levels and no elevation in basal blood glucose levels but rather a 
slight decline. These current findings are largely in line with observations of studies 
demonstrating impaired glucose stimulated insulin secretion after β-cell specific ablation 
of the IGF1R (215 -216). Mice exhibited reduced glucose stimulated insulin release, with 
unaltered β-cell mass, causing impaired glucose clearance in both studies. These findings 
were accompanied by a mild increase in basal insulin levels, at a comparable degree to 
our observations, maintaining basal serum glucose concentrations at a normal level. No 
peripheral insulin resistance was found in both studies. Furthermore, in vitro studies in 
the MIN-6 β-cell line revealed dysregulation of ATP level controlling mechanisms, 
contributing to glucose stimulated insulin release, after silencing of the IGF1R  (217). 
Although no increase of basal glucose levels was observed in IGF1R KD mice, impaired 
glucose clearance after insulin challenge indicated the development of peripheral insulin 
resistance due to IGF1R ablation. However, these effects seem to be relatively mild since 
elevated basal insulin levels were sufficient to maintain glucose homeostasis reflected by 
decreased basal blood glucose levels under physiological conditions compared to 
controls. In contrast to our observations, a severe diabetic phenotype was described for 
mice expressing a dominant negative IGF1R mutant in skeletal muscle, leading to 
functional inactivation of IGF1R and IR (70). These mice displayed hyperglycemia as 
well as a high degree of glucose and insulin resistance. The findings of this study were 
attributed to missing IGF1R function because IR ablation in muscle caused no distinct 
diabetic phenotype (27). Neither occurrence of serious insulin resistance nor development 
of hyperglycemia was confirmed in the present study, despite a considerable KD of 
IGF1R in muscle. In contrast to reduced body fat percentage in IR KD mice, ablation of 
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IGF1R caused a significant elevation in body fat content, accompanied by a body weight 
decline. Increased number and size of adipocytes were described after tissue specific 
ablation of IGF1R in white adipose tissue and was assumed to be a consequence of 
increased insulin-stimulated glucose uptake and subsequent lipogenesis (219). 
Furthermore, increased body fat content and decreased whole body weight were 
described after brain specific ablation of IGF1R as a secondary effect due to neural 
developmental defects disturbing the somatic axis and leading to reduced GH release 
(220) Indeed, GH-deficient mouse models display similar phenotype regarding fat 
content and body weight (221 -223). Certainly, lowered GH levels should cause a 
reduced IGF1 release, that was not observed in the present study but was detected after 
brain specific IGF1R KO (220). Indeed, Klöting et al. (219) demonstrated increased 
IGF1 release from adipocytes after ablation of IGF1R in adipose tissue that might in part 
compensate missing GH stimulation. 
However, in the current study the phenotypic changes observed in shIGF1R mice 
might result from both described effects on adipose tissue, since IGF1R silencing was 
ubiquitous in the applied model and GH levels were not determined. In conclusion, the 
findings of this and preceded studies demonstrate no diabetes-like phenotype in terms of 
lipid metabolism after ablation of IGF1R. However, detailed analyses of serum lipid 
species and specifically the expression of enzymes involved in lipid biosynthesis or 
breakdown in adipose tissue and liver are necessary to draw any further conclusions. 
Monitoring body weight over the course of the experiment revealed that mice with 
silencing in IGF1R did not gain weight after start of dox treatment. This stagnation can 
be attributed to disruption of somatic growth and changed food consumption behaviour, 
found in shIGF1R2 KD mice. Accordingly, a reduction of food intake was observed in 
rats after central administration of an IGF1R antagonist. (224). Furthermore, reduced 
food consumption can be a consequence of altered leptin release from adipocytes and 
subsequent changes in hypothalamic neuropeptide expression (225-230). Circulating 
serum leptin levels strongly correlate with adipocyte size and number (231-233), which 
were both elevated in mice with brain-specific but not adipocyte-specific IGF1R deletion 
(219, 220). Although no changed food intake behaviour was revealed by both studies, the 
4 Discussion 
                                                               
 
-100- 
 
inhibitory effects of leptin on calorie intake by acting on the central nervous system is 
well established (234-238). This assumption cannot be confirmed by the findings of this 
study because neither morphology of adipose tissue was analysed nor serum leptin levels 
were determined. Since food intake was monitored for just one week, we can not rule out 
the possibility that this effect was just temporary. The fact that body weight of mice with 
silencing in IGF1R just stagnated without severe reduction and displayed increased body 
fat content might indicate a temporary restricted change in food intake behaviour. If so, 
reduced weight gain would largely depend on disruption of somatic growth in mice with 
silencing in IGF1R, clearly demonstrated by reduced body length. Furthermore, reduced 
weight gain in not induced shIGF1R2 and shIGF1R2_shIR5 mice points to a disruption 
of the somatic axis due to constitutive shRNA expression in the brain even in the absence 
of dox. Growth retardation is a well-established phenotype of IGF1R loss-of-function 
mutants and was demonstrated in mice with conventional heterozygous deletion as well 
as after tissue specific ablation in brain and muscle (87, 220, 239, 240). Reduced body 
weight was either attributed directly to systemic disruption of IGF1 signaling or to neural 
developmental defects leading to reduced GH release in these studies (87, 219, 239).  
For the interpretation of the findings in double KD mice it must be considered that 
these displayed just approximately half of the silencing efficiency that was displayed by 
control group with single KD of IGF1R. Double KD mice, lacking IR and IGF1R, 
exhibited metabolic changes comparable to mice with single silencing in IR, displaying 
elevated blood glucose levels, compensatory insulin release, impaired glucose and insulin 
resistance as well as severe reduction of whole body weight and fat content.  
Neither onset kinetics nor degree of compensatory insulin release differed 
between mice lacking both receptors or just the IR, indicating either that insulin 
resistance is developed to the same extend, or compensatory mechanisms were activated 
at their maximum, in both mice lines. As demonstrated previously, IGF1R ablation 
caused impaired glucose-induced insulin release (215-217), but did not altered 
compensatory release in the present study, pointing to a dominant effect of β-cell mass 
expanison and enhanced function in response to target tissue resistance to insulin (241-
244). 
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Assessment of blood glucose levels in double KD mice revealed an earlier onset 
of hyperglycemia when compared to mice with single silencing in IR. This accelerated 
response might reflect a potential role of the IGF1R in insulin signaling. This finding is in 
line with the observed mild insulin resistance in mice with IGF1R ablation after insulin 
challenge. Possibly, hybrids of IR and IGF1R or even IGF1R homodimers maintain 
insulin signalling in the presence of severe hyperinsulinemia. Especially in the initial 
phase of compensatory insulin secretion, IR KD mice may still be able to dispose of the 
excess glucose via IGF1R signal transduction. However, this capability will be blunted in 
double KD mice, possibly explaining the sharper initial rise of blood glucose levels. 
However, function of IGF1R in this context does not seem to be critical enough to affect 
the overall magnitude of hyperglycemia in the further course of the experiment. The 
change in kinetics of glucose increment was the only significant finding indicating a 
worsening of a diabetic parameter between double KD and single IR KD mice. 
Furthermore, despite the observed gain of fat mass after IGF1R ablation (219-220), 
double KD mice lacking both receptors display a phenotype compliant with IR single KD 
in terms of reduced body fat content and the lack of epigonadal white fat pads, reflecting 
increased lipolysis and reduced uptake of lipids as a consequence of impaired insulin 
action on adipocytes. However, these findings in double KD mice cannot be clearly 
assigned to a dominant effect of IR ablation, since IGF1R reduction in adipose tissue of 
single KD mice is much more efficient compared to double KD mice. Further 
investigation on the expression of genes involved in lipogenesis and lipolysis might help 
to understand the interaction between IR and IGF1R ablation regarding lipid metabolism 
in adipocytes.  
Beside the metabolic changes, a multitude of physical parameters was altered in 
double KD mice, particularly a drastical reduction of body weight. Weight loss is a 
common diabetic symptom and was observed in IR single KD and, to a higher degree, in 
double KD mice. Increased weight loss of dKD mice can not be clearly attributed to a 
more severe affected energy metabolism, since double KD and IGF1R single KD mice 
displayed significantly reduction in food intake and somatic growth which might be seen 
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as the central factors in this context. Reduced food intake due to IGF1R ablation was 
described before (224) and might be a consequence of elevated fat mass leading to 
increased leptin release from adipocytes (219, 202). The possibility that changed food 
intake behavior was only transient must be considered, questioning the relevance of 
reduced food consumption for body weight reduction in mice with IGF1R KD. Growth 
retardation as a consequence of disturbing the somatic axis was an expected result of 
IGF1R KD (87, 220, 239), as described above, and was reflected by reduced body length 
of double KD mice to the same degree as in IGF1R single KD mice. Reduced food intake 
and somatic growth seem to be the most apparent factors by which IGF1R ablation 
contributes induces the drastic weight loss of double KD mice. However, contribution of 
metabolic effects to this phenotype cannot be ruled out. 
The simultaneous ablation of both receptors was lethal after 4 weeks. This 
increased mortality probably is a combinatory effect of disturbed glucose and lipid 
metabolism, reduced food intake behaviour and interrupted somatic growth. Due to the 
increased lethality all experiments were carried out in semi adult mice, up to 10 weeks of 
age. A potentially more important role of the IGF1R in aged mice was described by 
Bokov et al. (239) who observed progressive insulin resistance in heterozygous IGF1R 
KO mice of advanced age. The role of simultaneous silencing of IR and IGF1R in aged 
mice was not investigated and provides an interesting topic for follow-up studies. 
Taken together, simultaneous whole body silencing of the insulin and the IGF1 
receptor did not cause an enhanced middle-term diabetic phenotype in semi adult mice, 
displaying disturbance of glucose and lipid metabolism to the same extend as control 
mice with single ablation of the IR. Compensatory insulin release was undistinguishable 
between mice after silencing of IR or both IGF1R and IR receptor. Although mice with 
silencing of both receptors exhibited a more pronounced decline in body weight than IR 
KD mice, this decrease was rather a consequence of the combined effects of diabetic 
weight loss, reduced food intake and disturbed somatic growth, than due to a more 
pronounced impairment of metabolism. The only evidence for a worsening of metabolic 
parameters were the kinetics of developing hyperglycemia after silencing of both 
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receptors. This finding confirms the previously described ability of IGF1R receptors or 
IGF1R/IR hybrids to adopt functions of the IR and thereby contributing to insulin action, 
which was also demonstrated by a lowered response of peripheral tissues upon insulin 
challenge found in IGF1R single KD control mice. However, this phenotype appears 
relatively mild and was not observed under basal conditions, since neither the magnitude 
of hyperglycaemia, nor peripheral glucose disposal were altered between double KD 
mice and IR KD mice after the initial phase of induction. These findings suggest that 
IGF1R might display a compensatory function in marginal or pre-diabetic insulin 
resistance but is not a determining factor in severe loss of IR function in semi adult mice.  
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5 Summary 
Diabetes mellitus type 2 (T2DM) is a serious and frequent disease, characterized 
by deregulation of glucose metabolism as a consequence of dysfunction of the insulin 
signaling system. The relevance of the IGF1 receptor (IGF1R) in compensating functions 
of the structurally closely related insulin receptor (IR) was subject to several studies but 
has not been clarified so far. To investigate a possible redundant function of both 
receptors two strategies were pursued to obtain the simultaneous RNAi-mediated 
knockdown (KD) of both receptors in transgenic mice. The first strategy based on the 
generation of a ES cell line bearing two alleles prepared for recombinase mediated 
cassette exchange (RMCE) in the loci of Rosa 26 (R26) and Collagen, type I, α1 (Col1a1) 
facilitating the integration of two shRNA expression cassettes. The Functionality of 
double RMCE was demonstrated, although expression properties of the Collagen locus 
did not meet our requirements. As a second strategy two shRNA expression units 
allowing tet-repressor (tetR)-mediated temporal control of RNAi, were combined in a 
tandem construct, integrated into the Rosa26 locus of ES cells using RMCE technologie. 
Transgenic mice harbouring this tandem construct displayed temporal controllable RNAi, 
reducing IR expression to 15-25% and IGF1R expression to 20-45%. Simultaneous 
whole body silencing of both receptors did not cause an enhanced middle-term diabetic 
phenotype in semi adult mice, displaying disturbance of glucose and lipid metabolism to 
the same degree as mice with single ablation of the IR. A faster initial increase of blood 
glucose was observed in double KD mice, possibly a consequence of a rudimental ability 
of the IGF1R or IGF1R/IR hybrids to adopt functions of the IR, also demonstrated by a 
lowered response of IGF1R single KD mice on insulin challenge. Certainly this effect 
seems not to be distinct enough to appear after complete silencing of IR, since neither the 
magnitude of hyperglycaemia, nor peripheral glucose disposal were distinguishable 
between double KD mice and IR KD mice after the initial phase. These findings indicate 
that IGF1R might in part compensate loss of IR function in marginal or pre-diabetic 
insulin resistance but is not crucial in severe loss of IR function in semi adult mice. 
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6 Zusammenfassung 
Diabetes mellitus Typ 2 (T2DM) ist eine ernste und häufig auftretende 
Erkrankung, charakterisiert durch Defekte des Insulin Systems, die eine gestörte 
Glucosehomöostase zur Folge haben. Die Bedeutung einer möglichen Kompensation der 
Funktion des Insulinrezeptors (IR) durch den strukturell eng verwandten IGF1-Rezeptor 
(IGF1R) wurde in vielen Studien untersucht, aber bisher nicht eindeutig geklärt. Um eine 
potenzielle redundante Funktion der Rezeptoren untersuchen zu können, wurden zwei 
neuartige technologische Strategien verfolgt, durch die eine zeitgleiche RNAi vermittelte 
Hemmung der Expression beider Rezeptoren in transgenen Mäusen ermöglicht werden 
sollte. Im Rahmen der ersten Strategie wurde eine ES Zelllinie generiert, in der zwei 
genomische loci, Rosa26 und Collagen, type I, alpha 1 (Col1a1), mit RMCE-Kassetten 
präpariert wurden, um so die gleichzeitige Integration zweier shRNA-
Expressionskassetten zu ermöglichen. Die Funktionalität dieses doppelten RMCEs 
konnte erfolgreich demonstriert werden. Jedoch zeigte sich, dass die 
Expressionseigenschaften des Col1a1 Locus nicht alle notwendigen Bedingungen 
erfüllen. In einer zweiten Strategie wurden zwei shRNA-Expressionseinheiten, die eine 
tet-repressor (tetR) vermittelte zeitliche Kontrolle der RNAi erlaubten, in einem 
Tandemkonstrukt kombiniert. Dieses wurde mittel RMCE in den Rosa26 locus muriner 
ES Zellen integriert. Das Tandemkonstrukt erlaubte in transgenen Mäusen eine zeitliche 
Kontrolle des RNAi Effektes und die Reduktion der IR-Expression auf 15-25% sowie der 
IGF1R-Expression auf 20-45%. Die gleichzeitige ubiquitär unterdrückte Expression von 
IR und IGF1R bewirkte keinen verstärkten diabetischen Phänotyp in semiadulten 
Mäusen. Diese zeigten keinen Unterschied in der Beeinträchtigung des Glucose- und 
Lipidmetabolismus im Vergleich zu Mäusen, in denen nur die Expression des IR 
gehemmt wurde. Ein initial stärkerer Anstieg der Blutglucosewerte in Mäusen, in denen 
beide Rezeptoren herunterreguliert wurden, deutete auf eine mögliche Fähigkeit des 
IGF1R oder von IR/IGF1R-Hybriden hin, Funktionen des IR zu erfüllen. Einen weiteren 
Anhaltspunkt für eine redundante Funktion gab die abgeschwächte Reaktion IGF1R 
defizienter Mäuse auf die Stimulation mit Insulin. Allerdings scheint dieser Effekt nicht 
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ausgeprägt genug zu sein, um sich bei einem vollständigen Verlust des IR zu 
manifestieren, da im weiteren Verlauf des Experimentes keine Unterschiede in der 
Ausprägung der Hyperglycämie oder der peripheren Glucoseaufnahme festgestellt 
werden konnten. Diese Ergebnisse deuten darauf hin, dass der IGF1R teilweise den 
Verlust der IR-Funktion in schwach ausgeprägter oder prädiabetischer Insulinresistenz 
ausgleichen kann. Dieser Effekt scheint allerdings keine Bedeutung bei einem stark 
ausgeprägten Funktionsverlust des IR in semiadulten Mäusen zu haben.  
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